

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/029462 A1

(51) International Patent Classification⁷: **C12N 15/12**,
C07K 14/47, C12N 15/62, G01N 33/50, A61K 38/17

[DE/DE]; Max-Lehner-Strasse 18, 85354 Freising (DE).
SCHLEHUBER, Steffen [DE/DE]; Murstr. 21, 85356
Freising (DE).

(21) International Application Number: PCT/EP01/11213

(74) Agent: **VIERING, JENTSCHURA & PARTNER**;
Steinsdorfstr. 6, 80538 München (DE).

(22) International Filing Date:
27 September 2001 (27.09.2001)

(81) Designated State (*national*): US.

(25) Filing Language: English

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): **PIERIS
PROTEOLAB AG** [DE/DE]; Blumenstrasse 16, 85354
Freising-Weiherstephan (DE).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SKERRA, Arne**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/029462 A1

(54) Title: MUTEINS OF HUMAN NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND RELATED PROTEINS

(57) Abstract: Disclosed is a method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (Hngal), RAT, α_2 -microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target. The method comprises the steps of: (a) subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in a plurality of muteins of the proteins; and (b) enriching resulting muteins having binding affinity for a given target from the plurality of muteins by selected and/or isolating said muteins. Also disclosed are muteins obtainable by this method.

Muteins of human neutrophil gelatinase-associated lipocalin and related proteins

The present invention refers to a method for generating a mutein of human neutrophil gelatinase-associated lipocalin (hNGAL), rat α_2 -microglobulin-related protein (A2m) or mouse 24p3/uterocalin (24p3), wherein this mutein has detectable affinity to a given target and to a mutein of each of these three proteins obtainable by this method. The invention also refers to nucleic acids encoding such muteins, a pharmaceutical composition comprising a mutein of the invention as well as to various uses of the mutein of human neutrophil gelatinase-associated lipocalin, rat α_2 -microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3).

The lipocalins (Pervaiz and Brew, FASEB J. 1 (1987), 209-214) are a family of small, often monomeric secretory proteins which have been isolated from various organisms, and whose physiological role lies in the storage or in the transport of different targets, e.g. retinol or pheromones, as well as in more complex biological functions such as taste and olfaction or prostaglandin synthesis (reviewed, e.g., by Flower, Biochem. J. 318 (1996), 1-14). The lipocalins bear relatively little mutual sequence similarity and their relationship as a protein structural family was first elucidated by X-ray structural analysis (Sawyer et al., Nature 327 (1987), 659).

Typical targets of lipocalins are lipophilic substances of low molecular weight such as retinoids, fatty acids, cholesterol, prostaglandins, biliverdins, pheromones, tastants, and odorants (Flower, Biochem. J. 318 (1996), 1-14; see also Kjeldsen, Biochimica et Biophysica Acta, 1482 (2000), 272-283). A typical target for lipocalins is vitamin A in the case of the retinol-binding protein (Rbp) as well as β -lactoglobulin (Papiz et al., Nature 324 (1986), 383-385).

Antibodies, i.e. immunoglobulins, are a classical example for proteins which selectively bind targets by way of non-covalent interaction. These proteins play a crucial role as reagents in the fields of biotechnology, medicine,
5 bioanalytics as well as in the biological and life sciences in general. Despite manifold needs for binding proteins in conjunction with the recognition, binding or separation of ligands/targets, almost exclusively immunoglobulins are currently used for such purposes. The application of other
10 proteins with defined ligand-binding characteristics, for example the lectins, has remained restricted to special cases.

Recently, members of the lipocalin family have become the
15 subject of research concerning proteins having defined ligand binding properties. The German Offenlegungsschrift DE 197 42 706 and the international patent publication WO 99/16873 disclose the class of anticalins®; polypeptides which exhibit, like antibodies, specific binding characteristics
20 for a given ligand (cf. also Beste et al., Proc. Natl. Acad. Sci. USA, 96 (1999) 1898-1903). Anticalins® are obtainable starting from polypeptides of the lipocalin family which are mutated in those four segments that correspond to the sequence positions of the linear polypeptide sequence
25 comprising amino acid positions 28 to 45, 58 to 69, 86 to 99 and 114 to 129 of the Bilin-binding protein (Bbp).

In addition, the German patent DE 199 26 068, WO 00/75308 as well as Schlehuber et al., J. Mol. Biol. (2000), 1105-1120,
30 describe muteins of the Bilin-binding protein such as the muteins DigA and DigA16 which specifically bind digoxigenin.

Even though the anticalin® technology has in principle been established and has presumably yielded a promising practical
35 application in the digoxigenin-binding Bbp muteins described above, further improvements and practical applications are desirable. In view of the various potential applications for

ligand or target-binding proteins in the field of life sciences, the generation of anticalins® based on alternative lipocalin scaffolds would be desirable simply for the reason to have more options for practical realisation.

5

Accordingly, it is an object of the invention to provide alternative lipocalin muteins having binding affinity to a given target.

10 This object is solved by the method and the muteins with the features of the present independent claims.

Such a method is a method for generating a mutein of a protein selected from the group consisting of human
15 neutrophil gelatinase-associated lipocalin (hNGAL), rat α_2 -microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target, comprising the steps of:

(a) subjecting the protein to mutagenesis at one or more
20 of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in a plurality of muteins of the protein; and

(b) enriching resulting muteins having binding affinity
25 for a given target from the plurality of muteins by selection and/or isolating said mutein.

This means that the present invention is based on the finding that the human neutrophil gelatinase-associated lipocalin
30 (hNGAL) and the homologous proteins thereof from rat (A2m) and mouse (24p3) provide suitable scaffolds for the generation of proteins having binding activity to a given target of interest. hNGAL has been identified as a member of the lipocalin family and its three dimensional structure has
35 been solved by NMR (Coles et al., J. Mol. Biol. 289 (1999), 139-157) and by X-ray crystallography (Goetz et al., Biochemistry, 39 (2000), 1935-1941), but up to now neither

its physiological function nor its natural target have been unambiguously identified (Kjeldsen et al., supra). Accordingly, the present invention provides for the first time a possible practical application not only for hNGAL but
5 also for its homologues A2m and 24p3.

The amino acid positions in the proteins A2m and 24p3 which are subjected to mutagenesis in the method according to the invention are obtained from an alignment of the amino acid
10 sequences of hNGAL, A2m, and 24p3. In the protein A2m, which has the same number of amino acid residues (178) as hNGAL, the sequence positions which are used for the mutagenesis are identical to the positions selected in hNGAL, namely sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of
15 hNGAL. For 24p3, the corresponding sequence positions are the sequence positions 33 to 54, 66 to 85, 96 to 108, and 125 to 138. Thus, the amino acid positions which are subjected to mutagenesis are distributed across four sequence segments corresponding to four loops in the three-dimensional
20 structure of hNGAL, A2m, and 24p3.

The number of the segments (loops) defined above which are used for mutagenesis can vary. It is not necessary to mutate all four of these loops altogether, for example in a
25 concerted mutagenesis, but it is also possible to subject only two or three of the loops to generate a mutein having detectable affinity to a given target.

In a preferred embodiment of the method according to the invention, the respective protein, i.e. hNGAL, A2m or 24p3 is
30 subjected to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 40 to 50, 70 to 79, 101 to 103, and 125 to 132 of hNGAL. For example, if hNGAL is selected for the generation of a mutein,
35 hNGAL is subjected to mutagenesis at one or more of the sequence positions 40 to 50, 70 to 79, 101 to 103 and 125 to 132.

In a more preferred embodiment of the method, the respective protein is subjected to mutagenesis at one or more of the sequence positions which correspond to the sequence positions
5 40, 42, 44, 46, 47, 49, 50, 70, 72, 73, 77, 79, 101, 102, 103, 125, 127, 128, 130, and 132 of hNGAL.

In particularly preferred embodiments, at least 10 of the sequence positions 40, 42, 44, 46, 47, 49, 50, 70, 72, 73,
10 77, 79, 101, 102, 103, 125, 127, 128, 130, and 132 of hNGAL or A2m or of the corresponding positions of 24p3 are subjected to mutagenesis. In the most preferred embodiment, all of these 20 sequence positions are randomized, wherein it is preferred to allow all 20 naturally occurring amino acids
15 to be incorporated into the polypeptide sequences at these positions.

This means that the present invention is based on the finding that muteins of hNGAL or its homologues A2m and 24p3 having
20 detectable affinity to a given target can be obtained by mutagenesis, preferably random mutagenesis, of a total of 20 amino acid residues, namely the sequence positions 40, 42, 44, 46, 47, 49, 50, 70, 72, 73, 77, 79, 101, 102, 103, 125, 127, 128, 130, and 132 of hNGAL. This finding is particularly
25 surprising for several reasons.

As noted, a set of 20 amino acids in total is randomized, i.e. subjected to mutagenesis, in this preferred embodiment of the method of the invention, whereas a total of only 16
30 amino acids was mutated in WO 98/16873. When random NNS or NNK codon mutagenesis is used for the complete randomization of these 20 amino acid positions (i.e. each of the 20 natural amino acid is allowed at each of these selected 20 positions), 32^{20} possible codon combinations exist. If 16
35 amino acid positions are used for the randomization, 32^{16} possible codon combinations exist. Accordingly, increasing the number of amino acids which are subjected to random

mutagenesis by 4 (from 16 to 20) results in an increase by $32^4 \approx 10^6$ in the combinatorial complexity. However, the number of mutants which can be physically realized in the corresponding DNA-based library cannot be deliberately
5 increased due to experimental limitations and is usually restricted to a value of about $1 \cdot 10^9$ to $1 \cdot 10^{10}$ according to the state of the art. In one example of the present invention, a combinatorial DNA-based library containing just approximately $1 \cdot 10^7$ sequence variants (muteins) was used.

10 Considering that the small accessible section of the combinatorial sequence space is further reduced by a factor of approximately 10^6 , it is surprising that it is possible at all to isolate from a combinatorial library containing just
15 $1 \cdot 10^7$ such muteins of hNGAL (or A2m or 24p3) which a) do not only fold into soluble proteins but b) even have a new ligand/target specificity.

In this respect it should be noted that the approach taken
20 here is in contrast to the teachings of WO 99/16873. According to this reference it should be useful to maintain the total number of mutated amino acid positions within a single experiment as low as possible such that the collection of variants obtained by mutagenesis, i.e. the library, can in
25 its totality or, at least in a representative selection therefrom, be realized as completely as possible.

It should finally be noted that it is also surprising that the present approach is successfully used for the production
30 of a mutein having specific binding activity towards a protein epitope (cf. Example 5).

The present invention is also directed to a mutein of human neutrophil gelatinase-associated lipocalin, rat α_2 -
35 microglobulin-related protein (A2m) or mouse 24p3/uterocalin (24p3) having detectable affinity to a given target, which is obtainable by mutagenesis of the respective protein at those

sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL. Muteins are preferred which are obtainable by subjecting the respective protein to mutagenesis at the positions which correspond to the sequence positions 40 to 50, 70 to 79, 101 to 103, and 125 to 132 of hNGAL.

Preferably such a mutein carries an amino acid substitution at 5 to 10, more preferably at 8 to 12 or most preferred at 10 to 18 of the sequence positions.

In a preferred embodiment, the mutein has the amino acid sequence of SEQ ID NO: 12. This mutein is also referred to as TlpcA.

The muteins of the invention are able to bind the desired target with a detectable affinity, i.e. with an affinity constant of preferably at least 10^5 M^{-1} . Affinities lower than this are generally no longer measurable with common methods such as ELISA and are therefore of secondary importance for practical applications. Especially preferred are muteins which bind the desired target with an affinity of at least 10^6 M^{-1} , corresponding to a dissociation constant for the complex of $1 \text{ }\mu\text{M}$. The binding affinity of a mutein to the desired target can be measured by the person skilled in the art by a multitude of methods, for example by fluorescence titration, by competition ELISA or by the technique of surface plasmon resonance.

The target (ligand) which is bound by the mutein can be any chemical moiety that, for example, can also be recognized and bound by an immunoglobulin. Accordingly, the target can be a chemical compound in free or conjugated form which exhibits features of an immunological hapten, a hormone such as steroid hormones or any biopolymer or fragment thereof, for example, a peptide, a protein or protein domain, a peptide, an oligodeoxynucleotide, a nucleic acid, oligo- and

polysaccharides or another macromolecule or conjugates thereof. In a preferred embodiment of the invention, the target is a protein.

5 The muteins of the invention can have the natural amino acid sequence of hNGAL, A2m or 24p3 outside the mutated segments, i.e. the regions of the amino acid positions 33 to 54, 66 to 83, 94 to 106 and 123 to 136 in the case of hNGAL. On the other hand, the muteins disclosed here can also contain amino
10 acid mutations outside the positions subjected to mutagenesis compared to the wild-type protein as long as those mutations do not interfere with the binding activity and the folding of the mutein. This includes that, for example, mutations, substitutions, deletions, insertion of amino acid residues as
15 well as N- and/or C-terminal additions can be introduced into the natural amino acid sequence of hNGAL, A2m or 24p3.

Such modifications of the amino acid sequence of the selected protein within or without the selected binding region include
20 directed mutagenesis of single amino acid positions, for example in order to simplify the subcloning of the mutated lipocalin gene or its parts by incorporating cleavage sites for certain restriction enzymes. For example, the mutation Glu28 to His, and/or Thr145 to Ala can be introduced into the
25 hNGAL gene in order to simplify the cloning of the mutated gene segment via two new *Bst*XI restriction sites at these positions. Furthermore, mutations can be introduced within or without the four peptide loops in order to improve certain characteristics of the mutein of the protein chosen as
30 scaffold, for example its folding stability or folding efficiency or its resistance to proteases.

In a preferred embodiment, for instance, Cys87 of hNGAL is exchanged to Ser or Ala, whereby its covalent crosslinking
35 with other proteins such as gelatinase B (which might occur in *in vivo* applications of a mutein) can be prevented and its monomeric structure can be stabilized. Similarly, Cys

residues which may occur as a result of the mutagenesis and selection of the mutein of the invention are not always crucial for the binding of the given target and may be substituted by Ser or Ala in order to prevent covalent bond
5 formation or oxidation of the thiol group.

In a preferred mutein of hNGAL, Cys87 is substituted and/or the mutein carries one or both of the amino acid substitution Glu(28) -> His, Thr(145) -> Ala compared to hNGAL. In this
10 respect, it should be noted that the present invention is also directed to a (recombinant) hNGAL having the natural amino acid sequences in which only Cys87 has been substituted for any other suitable amino acid. This hNGAL polypeptide can be produced using the methods described here for the
15 production of the other muteins of the inventions (see Example 4), for example by use of the vector pHNGAL7.

The method of the present invention preferably comprises (in step (b)) (i) providing as the given target a compound which
20 is selected from the group consisting of a chemical compound in free or conjugated form which exhibits features of an immunological hapten, a peptide, a protein or another macromolecule, (ii) contacting the plurality of muteins with said target in order to allow formation of complexes between
25 said target and muteins having binding affinity for said target, and (iii) removing muteins having no or no substantial binding affinity.

No or no substantial binding affinity means under the used
30 conditions, no complex is formed between the target and the plurality of muteins which are contacted with the target. It is clear to the person skilled in the art that complex formation is dependent on many factors such as concentration of the binding partners, concentration of compounds acting as
35 competitors, ion strength of the buffers etc. The selection and enrichment is generally carried out under conditions which will allow isolation and enrichment of muteins having

an affinity constant of at least 10^5 M^{-1} to the target. However, the washing and elution steps can be carried out under varying stringency. For example, if muteins having an affinity constant of at least 10^6 M^{-1} are to be isolated, washing and elution can be performed under increased stringency, i.e. more stringent conditions. A selection with respect to the kinetic characteristics is also possible. The selection can, for instance, be performed under conditions which favor complex formation of the target with muteins that show a slow dissociation from the target (receptor), or in other words a low k_{off} rate.

The term "plurality" as used herein means that at least two muteins that differ from each other in their amino acid sequences are present. The upper limit of muteins generated by mutagenesis is usually restricted by the experimental conditions and is generally between 10^7 and 10^{12} .

The term "mutagenesis" as used herein means that the experimental conditions are chosen such that the amino acid naturally occurring at a sequence position of hNGAL, A2m or 24p3 can be substituted by at least one amino acid that is not present at this specific position in the respective natural polypeptide sequence. The term "mutagenesis" also includes to (additionally) modify the length of sequence segments by deletion or insertion of one or more amino acids. Thus, it is within the scope of the invention that, for example, one amino acid at a chosen sequence position is replaced by a stretch of three random mutations, leading to an insertion of two amino acid residues compared to the length of (the respective segment) of the wild-type protein. The term "random mutagenesis" means that no predetermined single amino acid (mutation) is present at a certain sequence position but that at least two amino acids can be incorporated into a selected sequence position during mutagenesis with a certain probability.

Such experimental conditions can, for example, be achieved by incorporating codons with a degenerate base composition in the structural gene for, e.g., hNGAL at those position which are to be mutated. For example, use of the codon NNK or NNS
5 allows incorporation of all 20 amino acids plus the amber stop codon during mutagenesis, whereas the codon VVS limits the number of possibly incorporated amino acids to 14 since it excludes the amino acids Cys, Ile, Leu, Met, Phe, Trp, Tyr, Val from being incorporated into the selected position
10 of the polypeptide sequence; use of the codon NMS, for example, restricts the number of possible amino acids to 11 at a selected sequence position since it excludes the amino acids Arg, Cys, Gly, Ile, Leu, Met, Phe, Trp, Val from being incorporated at a selected sequence position. In a preferred
15 embodiment of the method of the invention, a random mutagenesis is carried out, in which at least 4, preferably 6, more preferably 8 to 12 amino acids are allowed to be incorporated into a selected sequence position of hNGAL, A2m or 24p3. In a particularly preferred embodiment, at least one
20 sequence position is subjected to complete randomization, i.e. all 20 amino acids are allowed to be incorporated at this position during mutagenesis. From the above, it is also clear that the amino acid naturally present at a certain sequence position of the respective protein such as hNGAL can
25 also be present in the mutein after having subjected this position to mutagenesis.

In a preferred embodiment of the method of the invention, the target is a protein. The protein can be provided either in
30 free or conjugated form or as a fusion protein for the selection of muteins.

In a preferred embodiment of the method of the invention, a nucleic acid coding for the plurality of muteins of the
35 respective protein selected from hNGAL, A2m and 24p3 is used. This nucleic acid results from mutagenesis and it is operably fused at the 3' end with a gene coding for the coat protein

pIII of a filamentous bacteriophage of the M13-family or for a fragment of this coat protein, in order to select at least one mutein for the binding of the given target.

5 The nucleic acid that results from mutagenesis can be obtained by use of PCR. In a preferred embodiment of the method of the invention, the generation of the nucleic acid coding for the mutated segments of the respective protein comprises the following two steps. First, two nucleic acid
10 fragments, each of which codes for a part of the mutated protein are generated by PCR such that these fragments are partially overlapping. These fragments are employed with two flanking primers in a second amplification step in order to obtain the nucleic acid comprising the complete mutated
15 structural gene (see Fig.2 and Example 1 illustrating this two step procedure). Due to the overlap the full-length PCR product will be amplified in the course of this reaction, without that the addition of any additional nucleic acid is required. The two fragments can be obtained with a pair or
20 pairs of suitable primers in two separate amplification reactions (see also Fig.2 and Example 1, which shows that such two fragments are generated in PCR reactions A and B).

For some applications, it is useful to employ the inventive
25 mutein of hNGAL, A2m or 24p3 in a labelled form. Accordingly, the invention also refers to mutein of the each of the three proteins used as scaffold here which is which is conjugated to a label selected from the group consisting of enzyme label, radioactive label, fluorescent label, chromogenic
30 label, luminescent label, a hapten, biotin, digoxigenin, metal complexes, metals, and colloidal gold. The mutein can also be conjugated to an organic molecule. The term "organic molecule as used in the present application preferably means an organic molecule comprising at least two carbon atoms, but
35 not more than 7 rotatable carbon bonds having a molecular weight between 100 and 2000 Dalton, preferably 1000 Dalton and a molecule including one or two metal atoms.

In general, it is possible to label the mutein with any appropriate chemical substance or enzyme, which directly or indirectly generates in a chemical, enzymatic or physical reaction a detectable compound or a signal that can be used for detection. An example for a physical reaction is the emission of fluorescence after excitation with radiation or the emission of X-rays by a radioactive label; alkaline phosphatase, horseradish peroxidase or β -galactosidase are examples of enzyme labels which catalyse the formation of chromogenic (colored) compounds which can then be detection. In general all labels which are used for antibodies, except those which exclusively used with the sugar moiety in the Fc part of immunoglobulins can also be used for conjugation to the muteins of the present invention. These conjugates can be prepared by means of methods known to the person skilled in the art.

One option which is particularly advantageous for practical applications of the muteins disclosed here, is the use of the muteins in the form of fusion proteins. In preferred embodiments of such a fusion protein an enzyme, a protein or a protein domain, a peptide, for example a peptide such as a signal sequence and/or an affinity tag is operably fused to the amino terminus or to the carboxy terminus of the mutein.

The fusion partner can be suitable to confer new characteristics on the mutein, for example enzymatic activity or affinity for other molecules such as proteins, macromolecules or low molecular weight targets. For example, fusions with enzymes which catalyse chromogenic or fluorogenic reactions (e.g. alkaline phosphatase, horseradish peroxidase, glutathione-S-transferase) or which can serve for the liberation of cytotoxic agents are possible. Further examples of fusion partners which can be advantageous in practice are binding domains such as the albumin-binding domain of protein G, protein A, antibody fragments,

oligomerizing domains, toxins or also muteins of the invention or anticalins[®] with different or the same target specificity. A specific example for the latter would be a fusion protein comprising an hNGAL mutein of the present invention and the digoxigenin binding mutein DigA16 disclosed in the German Patent DE 199 26 068. Affinity tags such as the Strep-Tag[®] or the Strep-tag[®] II (Schmidt et al., J. Mol. Biol. 255 (1996), 753-766) or oligohistidine tags (e.g., His6-tags) or proteins such as glutathione-S-transferase which can be used for purification by affinity chromatography and/or for detection (e.g. using the specific affinity of the Strep-tag[®] for streptavidin) are further examples of preferred fusion partners. Proteins with chromogenic or fluorescent properties such as the green fluorescent protein (GFP) are suitable fusion partners, too.

The term fusion protein as used herein also includes muteins of the invention, for example muteins of hNGAL, that are equipped with a signal sequence. Signal sequences at the N-terminus of a polypeptide according to the invention can be suitable to direct the polypeptide to a specific cell compartment during the biosynthesis, for example into the periplasm of *E.coli* or to the lumen of the eukaryotic cell or into the medium surrounding the cell. In so doing, the signal sequence is cleaved by a signal peptidase. It is also possible to use other targeting or signalling sequences which are necessarily located at the N-terminus of the polypeptide and which allow the localization thereof in specific cell compartments. A preferred signal sequence for secretion into the periplasm of *E.coli* is the OmpA-signal sequence. A large number of further signal sequences is known in the art.

The invention is also directed to a nucleic acid molecule comprising a sequence encoding a mutein according to the invention or a fusion protein thereof. In a preferred embodiment the nucleic acid molecule comprises a nucleotide sequence encoding the mutein of SEQ ID NO. 12.

Since the degeneracy of the genetic code permits substitutions of certain codons by other codons which specify the same amino acid and hence give rise to the same protein, the invention is not limited to a specific nucleic acid molecule but includes all nucleic acid molecules comprising a nucleotide sequence coding for a mutein with the amino acid sequence according to the present invention.

10 The nucleic acid molecule comprising a nucleotide sequence encoding a mutein of any of hNGAL, A2m or 24p3 as disclosed here can be operably linked to a regulatory sequence to allow expression of the nucleic acid molecule in a host cell (in vivo) or its transcription and translation in a cell-free
15 system (in vitro).

A nucleic acid molecule such a DNA is regarded to be "capable of expressing of a nucleic acid molecule or a coding nucleotide sequence" or capable "to allow expression of a
20 nucleotide sequence" if it contains nucleotide sequences which contain transcriptional and translational information and if such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the
25 DNA sequences sought to be expressed are connected in such a way as to permit gene expression. The precise nature of the regulatory regions and elements needed for gene expression may vary from organism to organism, but shall, in general, include a promoter region which, in prokaryotes for example,
30 contains both the promoter regulatory sequence that can comprise a transcriptional region functional in a cell and a transcriptional terminating region functional in a cell. Elements used for transcription or translation are promoters, enhancers, leader sequences, transcription initiation sites
35 and transcripton termination sites, polyadenylation signals, ribosomal binding sites such the Shine-Dalgarno sequence and the like. These regulatory sequences and/or the mutein of the

invention can be part of a vector. Accordingly, the invention also refers to a vector comprising a nucleic acid sequence coding for a mutein of hNGAL, A2m or 24p3 as disclosed here.

- 5 In a further embodiment, the invention also relates to a method for producing of a mutein of the invention or a fusion protein thereof. In this method the mutein or the fusion protein is produced starting from the nucleic acid encoding the mutein by means of genetic engineering methods in a
- 10 bacterial or eukaryotic host organism and is isolated from this host organism or its culture. For this purpose a suitable host cell is usually first transformed with a vector comprising a nucleic acid molecule encoding, for instance, a NGAL mutein of the invention. The host cell, which can be any
- 15 prokaryotic or eukaryotic host cell is then cultured under conditions which allow the biosynthesis of the polypeptide. The polypeptide is then usually recovered either from the cell or from the cultivation medium. Since each of human neutrophil gelatinase-associated lipocalin, A2m and 24p3
- 20 contain one structural disulfide bond it is preferred to direct the polypeptide into a cell compartment having an oxidizing thiol/disulfide redox milieu by use of a suitable signal sequence. Such an oxidizing milieu is present in the periplasm of bacteria such as *E. coli* or in the lumen of the
- 25 endoplasm reticulum of a eukaryotic cell and usually favours the correct formation of the disulfide bonds. It is, however, also possible to produce a polypeptide of the invention in the cytosol of a host cell, preferably *E. coli*. In this case the polypeptide can, for instance, be produced in form of
- 30 inclusion bodies, followed by renaturation in vitro. A further option is the use of specifically mutated strains which have an oxidizing milieu in the cytosol and thus allow allow production of the native protein in the cytosol.
- 35 As evident from the above disclosure, the mutein of the present invention or a fusion or a conjugate thereof can be employed in many applications. In general, a mutein disclosed

here can be used in all applications antibodies are used in, except those with specifically rely on the glycosylation of the Fc part.

- 5 A preferred use of the mutein is the detection of a target by a mutein of the invention or a fusion protein thereof, which comprises the steps of contacting the mutein with a sample suspected of containing the given target under suitable conditions, thereby allowing formation of a complex between
- 10 the mutein and the given target, and determining the complexed mutein by a suitable signal. This signal can be caused by a label such as a fluorescent or chromogenic label as explained above. This signal can also be caused by the change of a physical properties which is caused by the
- 15 binding, i.e. complex formation itself. An example of such a properties is plasmon surface resonance the value of which is changed during binding of binding partners from which one is immobilized on a surface such as a gold foil.
- 20 As noted above, a mutein disclosed here and its derivatives can be employed in many areas similar to antibodies or their fragments. A mutein is preferably used for binding to a solid phase, so that the target of the mutein or a conjugate or a fusion protein of this target can be immobilized or
- 25 separated. Further preferred is the use of the mutein for labelling with an enzyme, an antibody or a radioactive substance or another group with a biochemical activity or with defined binding characteristics, so that the target of the mutein or a conjugate or a fusion protein of this target
- 30 can be detected or brought in contact with it. Muteins of the invention can serve for example in the detection of chemical structures by means of established bioanalytic methods such as ELISA or Western Blot, in microscopy or immunosensorics. Here, the detection signal can either be generated directly
- 35 by use of a suitable mutein conjugate or fusion protein or indirectly with detection of the bound mutein by means of an

antibody directed against it or for example by using an affinity tag.

Numerous possible applications for a mutein of hNGAL, A2m or 24p3 also exist in medicine. In addition to its use in diagnostics, a mutant polypeptide of the invention which binds for example tissue- or tumour-specific cellular surface molecules can be prepared. Such a mutein can, for example, be employed in conjugated form or as a fusion protein for "tumour imaging" or directly for cancer therapy.

Another related and preferred use of a mutein described here is the target validation, i.e. the examination whether a polypeptide that is assumed to be involved in the development of a disease or disorder is indeed somehow causative of the disease or disorder. This use for validation of the protein as a pharmacological drug target takes advantage of the ability of a mutein of the present invention to specifically recognize a surface area of a protein in its native conformation, i.e. the ability of a mutein disclosed here to bind to a native epitope. In this respect, it is to be noted that this ability to bind to a native epitope has been reported only for a limited number of recombinant antibodies, irrespective whether they have been produced by the classical immunization protocol of Köhler and Milstein (Nature 256 (1975), 495-497) or by combinatorial techniques such as phage display. The use of a mutein for validation of a drug target does not only comprises the detection of a target which is a protein, but also detection of a target which is a protein domain, a peptide, a nucleic acid molecule, an organic molecule or a metal complex.

In a further aspect, the invention refers to a pharmaceutical composition comprising a mutein of human neutrophil gelatinase-associated lipocalin, rat α_2 -microglobulin-related protein (A2m) or mouse 24p3/uterocalin (24p3) according to

the invention or a fusion protein thereof and a pharmaceutically acceptable carrier.

A mutein, for example a hNGAL mutein, of pharmaceutical interest can, for example, be a mutein having binding to tumour-specific cellular surfaces. It can also be a mutein which binds a specific drug and which serves as a "sustained release-release" form for this drug or a long-term storage of the drug in the body of a patient. Such a mutein can be administered by any therapeutically effective route for a proteinaceous pharmaceutical, e.g. parenterally, intranasally, rectally, buccally, or by inhalation via sprays or aerosols into the respiratory tract. Administration can occur in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles as desired. The term "parenteral" embraces delivery modes such as subcutaneous, intravenous, intramuscular, intrasternal, intra-arterial injection and infusion techniques. Due to the low molecular weight, inhalation is one of the preferred ways of administering a pharmaceutically useful mutein of the invention.

Accordingly, the mutein of the present invention can be formulated into compositions using both known pharmaceutically acceptable ingredients and methods of preparation. See, e.g., Remington et al., Pharmaceutical Sciences, 15th Ed., Mack Pub., Easton (1975).

For inhalation the muteins of the invention can be first placed into a particulate dispersed form. This can be accomplished by preparing an aqueous aerosol or solid particles which contain the respective polypeptide. Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the desired polypeptide together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers will vary depending upon the requirements for each polypeptide,

they can include nonionic surfactants (such as Tweens, Pluronics or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. The formulations also can include bronchodilating agents. The formulations will be sterile. Aerosols generally will be prepared from isotonic solutions. The particles optionally include normal lung surfactant proteins. Exemplary formulations for inhalation of proteins are disclosed in US Patent 6,099,517, for example. Administration of dry powder compositions for inhalation of a mutein of the invention is also possible. Suitable dry-powder formulations are described in US Patent 6,123,936, for example.

One option for preparing pharmaceutical compositions suitable for inhalation includes to form aerosols of particles in an aqueous or non-aqueous, e.g. fluorocarbon propellant, suspension. Such particles include, for example, intramolecular aggregates of the polypeptides or liposomal or microcapsular-entrapped polypeptides. The aerosols should be free of lung irritants, i.e. substances which cause acute bronchoconstriction, coughing, pulmonary edema or tissue destruction. However, nonirritating absorption enhancing agents are suitable for use herein.

Suitable compositions for parenteral administration comprise pharmaceutically acceptable sterile aqueous or non aqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or into dispersions, immediately prior to use. Representative examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols, e.g., - glycerol, propylene glycol, polyethylene glycol - and suitable mixtures thereof, vegetable oils, e.g., olive oil, and injectable organic esters such as ethyl oleate. Fluidity may be maintained by various means including the use of coating materials such as

lecithin, the maintenance of required particle size (in the case of dispersions) and surfactants.

5 The compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, dispersing agents, antibacterial and antifungal agents such as paraben, chlorobutanol, phenol and sorbic acid, isotonic agents such as sugars, sodium chloride, or agents which delay absorption such as aluminium monostearate and gelatin. The mutein may be
10 incorporated into slow or sustained release or targeted delivery systems such as polymer matrices, liposomes and microspheres.

Injectable formulations can be sterilized by numerous means,
15 including filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

20

The coding sequence for the each of the proteins used as scaffold here can serve as a starting point for mutagenesis of the peptide segments selected in the present invention. The coding sequence of hNGAL has been described by Bundgard
25 et al., Biochem. Biophys. Res. Commun. 202 (1994), 1468-1475. The coding sequence of A2m and 24p3, respectively has been published by Chan et al., Nucleic Acid Res. 16 (1988) 11638; and Stoesz et al., Oncogene 11 (1995), 2233-2241, for example. For the mutagenesis of the amino acids in the four
30 peptide loops, the person skilled in the art has at his disposal the various known methods for site-directed mutagenesis or for mutagenesis by means of the polymerase chain reaction. The mutagenesis method can, for example, be characterized in that mixtures of synthetic
35 oligodeoxynucleotides, which bear a degenerate base composition at the desired positions, can be used for introduction of the mutations. The use of nucleotide building

blocks with reduced base pair specificity, as for example inosine, is also an option for the introduction of mutations into the chosen sequence segment or amino acid positions. The procedure for mutagenesis of target-binding sites is simplified as compared to antibodies, since for hNGAL only four instead of six sequence segments - corresponding to the four above cited peptide loops - have to be manipulated for this purpose. A further possibility is the so-called triplet-mutagenesis. This method uses mixtures of different nucleotide triplets each of which codes for one amino acid for the incorporation into the coding sequence.

One of the various applicable methods for the introduction of mutations in the region of the four selected peptide loops of the scaffold proteins used here (i.e. in the case of hNGAL at sequence positions 33 to 54, 66 to 83, 94 to 106 and 123 to 136) is based on the use of four oligodeoxynucleotides, each of which is partially derived from one of the four corresponding sequence segments to be mutated. In the production of these oligodeoxynucleotides, the person skilled in the art can employ mixtures of nucleic acid building blocks for the synthesis of those nucleotide triplets which correspond to the amino acid positions to be mutated, so that codons or anticodons randomly arise for all amino acids or, according to the genetic code and to the composition of this mixture, for a selection of the desired amino acids at this position.

For example, the first oligodeoxynucleotide corresponds in its sequence - apart from the mutated positions - at least partially to the coding strand for the peptide loop, which is located in the polypeptide sequence of hNGAL at the most N-terminal position. Accordingly, the second oligodeoxynucleotide corresponds at least partially to the non-coding strand for the second sequence segment following in the polypeptide sequence. The third oligodeoxynucleotide corresponds in turn at least partially to the coding strand

for the corresponding third sequence segment. Finally, the fourth oligodeoxynucleotide corresponds at least partially to the non-coding strand for the fourth sequence segment. A polymerase chain reaction can be performed with the
5 respective first and second oligodeoxynucleotide and separately if needed, with the respective third and fourth oligodeoxynucleotide by using the nucleic acid which encodes the scaffold protein and/or its complementary strand as a template.

10

The amplification products of both of these reactions can be combined by various known methods into a nucleic acid which comprises the sequence from the first to the fourth sequence segments and which bears the mutations at the selected amino
15 acid positions. To this end, both of the products can for example be subjected to a new polymerase chain reaction using flanking oligodeoxynucleotides as primers as well as one or more mediator nucleic acid molecules which contribute the sequence between the second and the third sequence segment.

20

This procedure is schematically reproduced in **Fig.1**. In the choice of the number of the oligodeoxynucleotides used for the mutagenesis and their arrangement within the gene sequence of protein used, the person skilled in the art has furthermore numerous alternatives at his disposal.

25

The nucleic acid molecules which code for the sequence region encompassing the four peptide loops of the protein used and which contain mutations at the selected positions defined above can be connected by ligation with the missing 5'- and
30 3'-sequences of a nucleic acid coding for hNGAL, for example, and/or the vector, and can be cloned in a known host organism. A multitude of procedures are at one's disposal for the ligation and the cloning. For example, in the course of an amplification, synthetic nucleic acid molecules with
35 restriction endonuclease recognition sequences, which are also present at the corresponding positions in the nucleic acid sequence for hNGAL, can be attached at both ends of the

nucleic acid to be cloned so that a ligation is made possible following hydrolysis with the corresponding restriction enzyme. The missing 5'- and 3'-sequences of a nucleic acid coding for the respective lipocalin used in the present invention can also be attached to the nucleic acid molecule comprising the mutated sequence positions via PCR.

Longer sequence segments within the gene coding for the protein selected for mutagenesis can also be subjected to random mutagenesis via known methods, for example by use of the polymerase chain reaction under conditions of increased error rate, by chemical mutagenesis or by using bacterial mutator strains (Low et al., J. Mol. Biol. 260 (1996), 359-368). Such methods can also be used for the further optimization of the target affinity or target specificity of a mutein which has already been produced. Mutations which possibly occur outside the segments of the sequence positions 33 to 54, 66 to 83, 94 to 106 and 123 to 136 of hNGAL, for instance, can often be tolerated or can even prove advantageous, for example if they contribute to an improved folding efficiency or folding stability of the mutein.

After having brought the coding nucleic acid sequences that were subjected to mutagenesis to expression, the clones carrying the genetic information for the plurality of respective muteins which bind a given target can be selected from the library obtained. Known expression strategies and selection strategies can be employed for the selection of these clones. Methods of this kind have been described in the context of the production or the engineering of recombinant antibody fragments, such as the "phage display" technique (Hoess, Curr. Opin. Struct. Biol. 3 (1993), 572-579; Wells and Lowman, Curr. Opin. Struct. Biol. 2 (1992), 597-604) or "colony screening" methods (Skerra et al., Anal. Biochem. 196 (1991), 151-155) or "ribosome display" (Roberts, Curr. Opin. Chem. Biol. 3 (1999) 268-273).

An embodiment of the "phage display" technique (Hoess, supra; Wells and Lowman, supra; Kay et al., Phage Display of Peptides and Proteins - A Laboratory Manual (1996), Academic Press) is given here as an example of a selection method according to the invention for muteins with the desired binding characteristics. The various other possible embodiments of the "phage display" technique are hereby incorporated into the disclosure by reference. For the exemplary selection method, phasmids are produced which effect the expression of the mutated hNGAL structural gene as a fusion protein with a signal sequence at the N-terminus, preferably the OmpA-signal sequence, and with the coat protein pIII of the phage M13 (Model and Russel, in "The Bacteriophages", Vol. 2 (1988), Plenum Press, New York, 375-456) or fragments of this coat protein, which are incorporated into the phage coat, at the C-terminus. The C-terminal fragment Δ pIII of the phage coat protein, which contains only amino acids 217 to 406 of the natural coat protein pIII, is preferably used to produce the fusion proteins. Especially preferred is a C-terminal fragment from pIII in which the cysteine residue at position 201 is missing or is replaced by another amino acid.

The fusion protein can contain other components such as for example an affinity tag or an epitope sequence for an antibody which allows the immobilization or the later purification of the fusion protein or its parts. Furthermore, a stop codon can be located between the region coding for hNGAL or its mutein and the gene segment for the coat protein or its fragment, which stop codon, preferably an amber stop codon, is at least partially translated into an amino acid during translation in a suitable suppressor strain.

Phasmids here denote plasmids which carry the intergenetic region of a filamentous bacterial phage, such as for example M13 or f1 (Beck and Zink, Gene 16 (1981), 35-58) or a functional part thereof, so that during superinfection of the

bacterial cells with a helper phage, for example M13K07, VCS-M13 or R408, one strand of the circular phasmid DNA is packaged with coat proteins and is exported into the medium as so-called phagemid. On the one hand this phagemid has the hNGAL mutein encoded by the respective phasmid built into its surface as a fusion with the coat protein pIII or its fragment, wherein the signal sequence of the fusion protein is normally cleaved off. On the other hand it carries one or more copies of the native coat protein pIII from the helper phage and is thus capable of infecting a recipient generally a bacterial strain carrying an F- or F'-plasmid. In this way a physical coupling is ensured between the packaged nucleic acid carrying the genetic information for the respective hNGAL mutein, and the encoded protein which is at least partially presented in functional form on the surface of the phagemid.

The vector phNGAL5 (Fig.1) can for example be used in the construction of the phasmid with the sequences coding for the hNGAL muteins. The nucleic acid coding for the peptide loops can, for example, be inserted into the vector phNGAL5 via both of the *Bst*XI-restriction sites. Recombinant phasmids are incorporated by transformation into the *E. coli* strain, for example XL1-blue (Bullock et al., BioTechniques 5 (1987), 376-379) or TG1. In this way, clones are made which can produce many different hNGAL muteins as fusion proteins.

This library, i.e. the collection of the clones obtained, is subsequently superinfected in liquid culture according to known methods with an M13-helper phage. After this infection the incubation temperature of the culture can be reduced for production of the phagemids. Preferred incubation temperatures are those in which the optimal folding of the hNGAL mutein as a component of the fusion protein with the phage coat protein or its fragment is expected. During or after the infection phase the expression of the gene for the fusion protein with the hNGAL mutein can be induced in the

bacterial cells, for example by addition of anhydrotetracycline. The induction conditions are chosen such that a substantial fraction of the phagemids produced presents at least one hNGAL mutein. The phagemids are
5 isolated after a culture incubation phase of for example 6 to 8 hours. Various methods are known for isolation of the phagemids, such as for example precipitation with polyethylene glycol.

- 10 The isolated phasmids can be subjected to a selection by incubation with the desired target, wherein the target is present in a form allowing at least a temporary immobilization of those phagemids carrying muteins with the desired binding activity as fusion proteins in their coat.
- 15 Among the various embodiments known to the person skilled in the art, the target can for example be conjugated with a carrier protein such as serum albumin and be bound via this carrier protein to a protein binding surface, for example polystyrene. Microtiter plates suitable for ELISA techniques
20 or so-called "immuno-sticks" can preferably be used for this immobilization of the target. Alternatively, conjugates of the target can also be implemented with other binding groups such as for example biotin. The target can then be immobilized on surfaces which selectively bind this group,
25 such as for example microtiter plates or paramagnetic particles coated with streptavidin or avidin.

- Residual protein- or phagemid-binding sites present on the surfaces which are charged with targets can be saturated with
30 blocking solutions known for ELISA-methods. The phagemids are for example subsequently brought in contact in a physiological buffer with the target immobilized on the surface. Unbound phagemids are removed by multiple washings. The phagemid particles remaining on the surface are
35 subsequently eluted. For elution, the free target can be added as a solution. But the phagemids can also be eluted by addition of proteases or, for example, in the presence of

acids, bases, detergents or chaotropic salts, or under moderately denaturing conditions. A preferred method is the elution using buffers of pH 2.2, wherein the eluate is subsequently neutralized.

5 Afterwards, *E. coli* cells are infected with the eluted phagemids using generally known methods. The nucleic acids can also be extracted from the eluted phagemids and be incorporated into the cells in another manner. Starting from
10 the *E. coli* clones obtained in this way, phagemids are in turn generated by superinfection with M13-helper phages according to the method described above and the phagemids propagated in this way are once again subjected to a selection on the surface with the immobilized target.
15 Multiple selection cycles are often necessary in order to obtain the phagemids with the muteins of the invention in enriched form. The number of selection cycles is preferably chosen such that in the subsequent functional analysis at least 0.1 % of the clones studied produce muteins with
20 detectable affinity for the given target. Depending on the size, i.e. the complexity of the library employed, 2 to 8 cycles are typically required to this end.

For the functional analysis of the selected muteins, an *E.*
25 *coli* strain is infected with the phagemids obtained from the selection cycles and the corresponding double stranded phasmid DNA is isolated. Starting from this phasmid DNA or also from the single-stranded DNA extracted from the phagemids, the nucleic acid sequences of the selected muteins
30 of the invention can be determined by the methods common for this purpose and the amino acid sequence can be derived therefrom. The mutated region or the sequence of the entire hNGAL mutein can be subcloned in another expression vector and expressed in a suitable host organism. phNGAL7 can for
35 example be used as the expression vector (cf. Fig.3) and the expression with phNGAL7 derivatives can be performed in *E. coli* strains, for example *E.coli*-TG1. The muteins of hNGAL

produced by genetic engineering can be purified by various proteinchemical methods. The hNGAL muteins produced for example with phNGAL7 carry the affinity peptide Strep-Tag II (Schmidt et al., supra) at their C-terminus and can therefore preferably be purified by streptavidin affinity chromatography.

The selection can also be carried out by means of other methods. Many corresponding embodiments are known to the person skilled in the art or are described in the literature. A combination of methods can also be applied. For example, clones selected or at least enriched by "phage display" can additionally be subjected to a "colony screening". This procedure has the advantage that individual clones can directly be isolated with respect to the production of a hNGAL mutein with detectable binding affinity for a target.

In addition to the use of *E. coli* as host organism in the "phage display" technique or the "colony screening" method, other bacterial strains, yeast or also insect cells or mammalian cells can for example be used for this purpose. In addition to the selection of an hNGAL mutein from a primary library produced starting from a coding nucleic acid sequence for a mutein, comparable methods can also be applied in order to optimize a mutein with respect to the affinity or specificity for the desired target by repeated, optionally limited mutagenesis of its coding nucleic acid sequence.

It is surprising that by use of the method of the invention hNGAL muteins can be isolated which show detectable affinity to a given target (cf. Examples 4, 5).

It is additionally possible to subject the muteins produced to a further, optionally partial random mutagenesis in order to select variants of even higher affinity from the new library thus obtained. A corresponding procedures have already been described for the case of digoxigenin binding

muteins of the bilin-binding protein for the purpose of an "affinity maturation" (DE 199 26 068, WO 00/75308; Schlehuber et al., supra) and can also be applied to a mutein disclosed here in a corresponding manner by the person skilled in the art.

The invention is further illustrated by the following examples and the attached drawings in which:

Figure 1 schematically depicts the phasmid vector pHNGAL5;

Figure 2 schematically illustrates the production of the library of lipocalin muteins at the nucleic acid level;

Figure 3 schematically depicts the expression vector pHNGAL7;

Figure 4 schematically depicts the expression vector pTLpc3;

Figure 5 depicts the binding of the mutein TlpcA to Tear lipocalin and a corresponding control experiment with hNGAL using ELISA.

Fig.1 shows a schematic drawing of pHNGAL5. This vector codes for a fusion protein of the OmpA signal sequence, a modified hNGAL with the three amino acid substitutions Gln28 to His, Leu137 to Ile as well as Thr145 to Ala, the Strep-Tag II affinity tag and a shortened form of the M13 coat protein pIII, comprising the amino acids 217 to 406 (pIII). The entire structural gene is subject to the transcriptional control of the tetracycline promoter/operator ($tet^{P/O}$) and ends at the lipoprotein transcription terminator (t_{lpp}).

Further elements of the vector are the origin of replication (ori), the intergenic region of the filamentous bacteriophage f1 (f1-IG), the ampicillin resistance gene (bla) coding for

β -lactamase and the tetracycline repressor gene (tetR). An amber stop codon, which is partially translated into Gln in SupE amber suppressor host strain, is located between the coding region for hNGAL with the OmpA signal sequence and the Strep-Tag II as well as the coding region for the truncated phage coat protein pIII. Both the two BstXI-restriction sites used for the cloning of the mutated gene cassette and the restriction sites flanking the structural gene are labelled. A relevant segment from the nucleic acid sequence of phNGAL5 is reproduced together with the encoded amino acid sequence in the sequence protocol as SEQ ID NO:7. The segment begins with an XbaI restriction site and ends with the HindIII restriction site. The vector elements outside this region are identical with those of the vector pASK75, the complete nucleotide sequence of which is given in the German patent publication DE 44 17 598 A1.

Fig.2 schematically shows a strategy for the concerted mutagenesis of 20 selected amino acid positions in the hNGAL by repeated application of the polymerase chain reaction (PCR). For each of the four peptide loops in which the amino acids are to be mutated, an oligodeoxynucleotide was synthesized, (SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4), wherein the respective mixtures of the nucleotides given in the sequence protocol were employed at the mutation sites. Due to the composition chosen, from the altogether three possible stop codons only the amber stop codon, TAG, was allowed at the mutated codons, which is translated as glutamine in the *E. coli* supE-strains XL1-blue (Bullock et al., BioTechniques 5 (1987), 376-378) or TG1 (Sambrook et al., Molecular Cloning. A Laboratory Manual (1989), Cold Spring Harbor Press) that were used for gene expression. For certain applications, for example for gene expression in other bacterial strains or organisms, such a nonsense codon, when it arises in the structural gene for a selected hNGAL mutein, can be substituted by a glutamine-encoding codon by the person skilled in the art, for example via site-directed

mutagenesis. A nucleic acid fragment with 168 base pairs was amplified (1. PCR, PCR A) with the primers SEQ ID NO:1 and SEQ ID NO:2 using the pHNGAL3-plasmid-DNA (SEQ ID NO:8) containing the cloned hNGAL cDNA as template. In another PCR, a nucleic acid fragment with 179 base pairs was amplified (1. PCR, PCR B) with the primers SEQ ID NO:3 and SEQ ID NO:4, also using pHNGAL3 as template. pHNGAL3 differs from pHNGAL5 only by two missing *Bst*XI restriction sites at positions 283 and 630 and one further *Bst*XI restriction site at position 675, showing the hNGAL wildtype sequences there. The mixture of both PCR products, which were partially overlapping, served as template in another amplification (2. PCR) with the two flanking PCR primers SEQ ID NO:5 and SEQ ID NO:6, wherein a gene fragment of 386 base pairs was obtained. This fragment contained the mixture of all 20 mutated codons and was subsequently cloned using the two *Bst*X restriction sites on the vector pHNGAL5. The use of these two restriction sites, the special arrangement of which led to two non-compatible overhanging DNA ends during the restriction digest, enabled a particularly efficient ligation. The substitution of the amino acids Gln28 to His and Thr145 to Ala with respect to the original sequence as well as a silent mutation in the codon for Ser156 were previously accomplished during the construction of pHNGAL5 in order to introduce both of the *Bst*XI restriction sites into the hNGAL structural gene.

Fig.3 shows a drawing of pHNGAL7. pHNGAL7 codes for a fusion protein made of the OmpA-signal sequence, a modified hNGAL according to Fig.1, the Strep-Tag® II affinity tag, and an albumin-binding domain (abd) of protein G from *Streptococcus* (Kraulis et al., FEBS Lett. 378 (1996), 190-194). All further genetic elements are identical with pHNGAL5. A relevant segment from the nucleic acid sequence of pHNGAL7 is reproduced together with the encoded amino acid sequence in the sequence protocol as SEQ ID NO:9. The segment begins with the *Xba*I-restriction site and ends with the *Hind*III restriction site. The vector elements outside this region are

identical with the vector pASK75, the complete nucleotide sequence of which is given in the German patent publication DE 44 17 598 A1.

5 Fig.4 shows a drawing of pTLpc3. pTLpc3 codes for a fusion protein made of the OmpA-signal sequence, a modified human Tear Lipocalin with the amino acid substitution Cys97 to Ser and, the Strep-Tag® II affinity tag. All further genetic elements are identical with phNGAL5. A relevant segment from
10 the nucleic acid sequence of pTLpc3 is reproduced together with the encoded amino acid sequence in the sequence protocol as SEQ ID NO:9. The segment begins with the *Xba*I-restriction site and ends with the *Hind*III restriction site. The vector elements outside this region are identical with the vector
15 pASK75, the complete nucleotide sequence of which is given in the German patent publication DE 44 17 598 A1.

Fig.5 shows a graphical representation of the data from Example 5, in which binding measurements with the hNGAL
20 mutein TlpcA were performed by Enzyme-linked Immunosorbent Assay (ELISA). Binding of TlpcA and Tear lipocalin (squares) was compared to the interaction of hNGAL and Tear lipocalin (open circles). TlpcA binds Tear lipocalin in a concentration-dependent manner. hNGAL does not show a
25 significant binding signal.

Examples

30 Example 1: Production of a library for hNGAL muteins

Unless otherwise indicated, genetic engineering methods known to the person skilled in the art were used, as for example described in Sambrook et al.(supra).

35

PCR was applied in multiple steps according to Figure 2 for the concerted mutagenesis of in total 20 selected amino acid

positions in the four peptide loops of hNGAL. The PCR reactions were carried out in a volume of 100 μ l in both of the first amplification steps, wherein 20 ng phNGAL3 plasmid DNA was employed as template together with 50 pmol of each of the respective primers (SEQ ID NO:1 and SEQ ID NO:2 or SEQ ID NO:3 and SEQ ID NO:4, respectively), which had been synthesized according to the conventional phosphoramidite method. In addition, the reaction mixture contained 10 μ l 10xTaq buffer (100 mM Tris/HCl pH 9,0, 500 mM KCl, 15 mM MgCl₂, 1% v/v Triton X-100), 10 μ l dNTP-Mix (2 mM dATP, dCTP, dGTP, dTTP). After bringing to volume with water, 5 u Taq DNA-polymerase (5 u/ μ l, Promega) were added and 20 temperature cycles of 1 minute at 94 °C, 1 minute at 60 °C and 1.5 minutes at 72 °C were carried out in a thermocycler with a heated lid (Eppendorf), followed by an incubation for 5 minutes at 60 °C. The desired amplification products were isolated by preparative agarose gel electrophoresis from Low Melting Point Agarose (Roche Diagnostics) using the Jetsorb DNA extraction kit (Genomed).

20

The subsequent amplification step was also carried out in a 100 μ l mixture, wherein approximately 6 ng of both of these respective fragments were used as templates, in the presence of 50 pmol of each of the primers SEQ ID NO:5 and SEQ ID NO:6. The remaining components of the PCR mixture were added in the same amounts as in the previous amplification steps. PCR took place with 20 temperature cycles of 1 minute at 94 °C, 1 minute at 55 °C, 1.5 minutes at 72 °C, followed by a subsequent incubation for 5 minutes at 60 °C. The PCR product was purified using the E.Z.N.A. Cycle-Pure Kit (PqLab).

30

For the cloning of this fragment, which represented the library of the hNGAL muteins in nucleic acid form, it was first cut with the restriction enzyme *Bst*XI (New England Biolabs) according to the instructions of the manufacturer and purified by means of the E.Z.N.A. Cycle-Pure Kit. After a second restriction digest with *Bst*XI, the nucleic acid

35

fragment was purified by preparative agarose gel electrophoresis, resulting in a double stranded DNA-fragment of 347 nucleotides in size. The DNA of the vector phNGAL5 was cut with *Bst*XI in the same manner and the larger of the two resulting fragments (3971 bp) was isolated.

For the ligation, 2.75 µg (12 pmol) of the PCR fragment and 31.45 µg (12 pmol) of the vector fragment was incubated in the presence of 180 Weiss Units T4 DNA ligase (New England Biolabs) in a total volume of 600 µl (50 mM Tris/HCl pH 7.8, 10 mM MgCl₂, 10 mM DTT, 1 mM ATP, 50 µg/ml BSA) for four days at 16 °C. The DNA was subsequently precipitated by adding 50 µg tRNA from yeast (Boehringer Mannheim), 125 µl 5 M ammonium acetate and 500 µl ethanol per 120 µl of ligation mixture. Incubation at -20 °C for three days was followed by centrifugation (30 minutes, 16000 g, 4 °C). Each precipitate was washed with 750 µl ethanol (70% v/v, -20°C), centrifuged (5 minutes, 16000 g, 4 °C), and dried under vacuum (2 minutes). The DNA was finally dissolved in 200 µl TE/10 (1 mM Tris/HCl pH 8.0, 0.1 mM EDTA pH 8.0) and adjusted with water to a final volume of 260 µl.

The preparation of electrocompetent cells of the *E. coli* K12 strain XL1-blue (Bullock et al., supra) was carried out according to the methods described by Tung and Chow (Trends Genet. 11 (1995), 128-129) and by Hengen (Trends Biochem. Sci. 21 (1996), 75-76). 1 l LB-medium was adjusted by addition of a stationary XL1-blue overnight culture to an optical density at 600 nm of OD₆₀₀ = 0.08 and was incubated at 200 rpm and 26 °C in a 2 l Erlenmeyer flask. After reaching an OD₆₀₀ = 0.6, the culture was cooled for 30 minutes on ice and subsequently centrifuged for 15 minutes at 4000 g and 4 °C. The cell sediment was washed twice each with 500 ml ice-cold 10% w/v glycerol and was finally resuspended in 2 ml of ice-cold GYT-medium (10 % w/v glycerol, 0.125 % w/v yeast extract, 0.25 % w/v tryptone).

The Micro Pulser system (BioRad) was used with the cuvettes from the same vendor (electrode separation 2 mm) for the electroporation. All steps were carried out in the cold room at 4 °C. Each 5 µl of the DNA solution mentioned above was
5 mixed with 40 µl of the cell suspension, incubated for 1 minute on ice and finally transferred to the cuvette. After the electroporation the suspension was immediately diluted in 2 ml of ice-cold SOC-medium (2 % w/v tryptone, 0.5 % w/v yeast extract, 10 mM NaCl, 10 mM MgSO₄, 10 mM MgCl₂) and was
10 shaken for 60 minutes at 37 °C and 200 rpm. The culture was diluted in 2 l 2xYT-medium with 100 µg/ml ampicillin (2YT/Amp) and cultivated until the OD₅₅₀ caused by the replicating cells was raised to 0.64. By employing in total 34.2 µg of the ligated DNA, 7x10⁷ transformants were obtained
15 in this way with 49 electroporation runs. The transformants were further used according to Example 2.

Example 2: Phagemid presentation and selection of hNGAL muteins against human Tear Lipocalin

20

200 ml of the culture, containing the cells which were transformed with the phasmid vectors similar to phNGAL5 coding for the library of the lipocalin muteins as fusion proteins, were transferred to a sterile Erlenmeyer flask.
25 After infection with VCS-M13 helper phage (Stratagene) at a multiplicity of infection of approximately 10 the culture was shaken for additional 30 minutes at 37 °C, 160 rpm. Kanamycin (70 µg/ml) was subsequently added, the incubator temperature was lowered to 30 °C and, after 10 minutes,
30 anhydrotetracycline (ACROS Organics) was added at 100 µg/l (200 µl of a 100 µg/ml stock solution in dimethylformamide, DMF) in order to induce gene expression. Incubation continued for another 5 hours at 30 °C, 160 rpm.

35 50 ml were removed from this culture and the cells were sedimented by centrifugation (15 minutes, 12000 g, 4 °C). The supernatant containing the phagemid particles was sterile-

filtered (0.45 μ m), mixed with 1/4 volume (12.5 ml) 20 % w/v PEG 8000, 15 % w/v NaCl, and incubated overnight at 4 °C. After centrifugation (20 minutes, 18000 g, 4 °C) the precipitated phagemid particles were dissolved in 2 ml of
5 cold PBS (4 mM KH_2PO_4 , 16 mM Na_2HPO_4 , 115 mM NaCl, pH 7.4). The solution was incubated on ice for 30 minutes and was distributed into two 1.5 ml reaction vessels. After centrifugation of undissolved components (5 minutes, 18500 g, 4 °C) each supernatant was transferred to a new reaction
10 vessel.

Mixture with 1/4 volume 20 % w/v PEG 8000, 15 % w/v NaCl and incubation for 30 to 60 minutes on ice served to reprecipitate the phagemid particles. After centrifugation
15 (20 minutes, 18500 g, 4 °C) the supernatant was removed and the precipitated phagemid particles were dissolved and combined in a total of 400 μ l PBS. After incubation for 30 minutes on ice the solution was centrifuged (5 minutes, 18500 g, 4 °C) in order to remove residual aggregates and the
20 supernatant was used directly for the affinity enrichment.

Immuno-sticks (NUNC) were used for the affinity enrichment of the recombinant phagemids carrying the hNGAL mutein fusion proteins. These were coated overnight with 800 μ l of human
25 Tear Lipocalin (Tlpc) (450 μ g/ml) in PBS.

For the production of recombinant Tlpc, cells of *E. coli* JM83 (Yanisch-Perron et al., Gene 33 (1985), 103-119) were transformed with the expression plasmid pTLpc3 harbouring the
30 cDNA of Tlpc (for the cDNA of Tlpc, see Holzfeind and Redl, Gene 139 (1994), 177-183) and used for protein production and purification according to example 3. The protein yield was approximately 2.2 mg per 1 l culture volume.

35 Unoccupied binding sites on the surface of the Immuno-Stick were saturated by incubation with 1.2 ml 2% w/v BSA in PBST (PBS with 0.1 % v/v Tween 20) for 2 hours at RT. Afterwards

the Immuno-Stick was incubated with a mixture of 250 μ l of the phagemid solution and of 500 μ l of blocking buffer (3 % w/v BSA in PBST) for 1 hour at RT.

- 5 For the removal of unbound phagemids, washing was performed eight times, each time with 950 μ l PBST for 2 minutes. Adsorbed phagemids were finally eluted by 10 minute treatment of the Immuno-Stick with 950 μ l 0.1 M glycine/HCl pH 2.2, followed by immediate neutralisation of the pH of the elution
10 fraction by mixing it with 150 μ l 0.5 M Tris.

For the amplification, this phagemid solution (1.1 ml, containing between 10^6 and 10^8 Colony-forming Units, depending on the selection cycle) was shortly warmed to 37
15 $^{\circ}$ C, mixed with 3 ml of an exponentially growing culture of *E. coli* XL1-blue ($OD_{550} = 0.5$), and incubated for 30 minutes at 37 $^{\circ}$ C, 200 rpm. The cells infected with the phagemids were subsequently sedimented (2 minutes, 4420 g, 4 $^{\circ}$ C), resuspended in 600 μ l of the culture medium, and plated out
20 onto three agar plates with LB-medium containing 100 μ g/ml ampicillin (LB/Amp; 140 mm diameter).

After incubation for 14 hours at 32 $^{\circ}$ C, the cells were scraped from the agar plates, each with addition of 10 ml
25 2xYT/Amp-medium, were transferred to a sterile Erlenmeyer-flask, and were shaken for 20 minutes at 37 $^{\circ}$ C, 200 rpm for complete suspension. 200 ml of 2xYT/Amp-medium prewarmed to 37 $^{\circ}$ C were inoculated to an $OD_{550} = 0.08$ with an appropriate volume of this suspension.

30

For the repeated production and affinity enrichment of phagemid particles the same procedure as described at the beginning of this example was used. In these cases 50 ml 2xYT/Amp-medium was inoculated with 0.2 to 1 ml of the
35 suspension of the cells grown on the agar plates and phagemids were produced during a period of seven instead of

five hours at 30 °C. Four further selection cycles with the Tlpc were carried out in this way.

Example 3: Identification of human Tear Lipocalin-binding hNGAL muteins by use of the "colony screening"-method

For the analytical production of the hNGAL muteins as fusion proteins with the Strep-Tag® II as well as with the albumin-binding domain and their characterization by colony screening, the gene cassette between the two *Bst*XI cleavage sites was subcloned from the vector phNGAL5 on phNGAL7.

For this purpose the phasmid DNA was isolated from the mixture of the *E. coli* clones obtained by infection with the phagemids from Example 2 eluted as a result of the last selection cycle, using the Perfectprep Plasmid Midi Kit (Eppendorf). The DNA was cut with the restriction enzyme *Bst*XI and the smaller of the two fragments (347 bp) was purified by preparative agarose-gel electrophoresis as described in Example 1. The DNA of the vector phNGAL7 was cut with *Bst*XI and the larger of the two fragments (3971 bp) was isolated in the same way.

For the ligation, each 100 fmol of the two DNA-fragments were mixed with 1.5 Weiss Units T4 DNA ligase (Promega) in a total volume of 20 µl (30 mM Tris/HCl pH 7.8, 10 mM MgCl₂, 10 mM DTT, 1 mM ATP), followed by incubation overnight at 16 °C. *E. coli* TG1-F⁻ (*E. coli* K12 TG1, which had lost its episome through repeated culturing under non-selective conditions) was transformed with 2 µl of this ligation mixture according to the CaCl₂-method (Sambrook et al., supra).

A hydrophilic PVDF membrane (Millipore, type GVWP, pore size 0.22 µm), labelled at one position and cut to size, was laid onto an LB/Amp agar plate. 150 µl of the cell suspension from the transformation batch, which had been centrifuged (5000 g, 2 min, 4 °C) and resuspended in 500 µl of the culture medium,

were uniformly plated onto this membrane. The agar plate was incubated for 7.5 hours at 37 °C until the colonies had reached a size of approximately 0.5 mm.

- 5 In the meantime a hydrophobic membrane (Millipore, Immobilon P, pore size 0.45 µm), also cut to size, was moistened with PBS according to the instructions of the manufacturer. It was subsequently agitated for 4 hours at RT in a solution of 10 mg/ml human serum albumin (HSA, Sigma) in PBS. Remaining
10 binding sites on the membrane were saturated by incubation with 3 % w/v BSA, 0.5 % v/v Tween 20 in PBS for 2 hours at RT. The membrane was washed twice for 10 minutes each with 20 ml PBS and agitated afterwards for 10 minutes in 10 ml LB/Amp medium, to which 200 µg/l anhydrotetracycline were added. It
15 was subsequently marked at one position and was laid onto a culture plate with LB/Amp agar, which additionally contained 200 µg/l anhydrotetracycline. The hydrophilic membrane on which the colonies were grown was laid onto the hydrophobic membrane in such a way that both of the marks superimposed.
20 The culture plate was incubated with both membranes at 22 °C for 15 hours. During this phase the respective hNGAL muteins were secreted from the colonies and were immobilized via the albumin-binding domain on the HSA on the lower membrane.
- 25 After this, the upper membrane with the colonies was transferred to a fresh LB/Amp agar plate and stored at 4 °C. The hydrophobic membrane was removed, washed three times for 5 minutes each with 20 ml PBST, and subsequently incubated for 1 hour in 10 ml of a solution of a conjugate (10 µg/ml)
30 from Tear lipocalin and biotin in PBST. For the production of the conjugate, a solution of 0.285 mg D-biotinoyl-ε-amidocaproic acid-N-hydroxysuccinimide ester (Roche) in 9 µl DMSO was slowly added to 2.5 ml of 450 µg/ml Tlpc in 5 % w/v NaHCO₃ (pH 8.2). After stirring for 1 hour at RT, excess
35 reactant was removed by means of a PD-10 gel filtration column (Pharmacia) using PBS as running buffer.

After incubation with the conjugate, the membrane was washed three times with PBST, followed by incubation for 1 hour with 10 ml avidin-alkaline-phosphatase conjugate (Sigma, dilution 1:40000 in PBST). The membrane was subsequently washed each
5 twice with PBST and once with PBS for 5 minutes and agitated for 10 minutes in AP-buffer (0.1 M Tris/HCl pH 8.8, 0.1 M NaCl, 5 mM MgCl₂). For the chromogenic reaction, the membrane was incubated in 10 ml AP-buffer, to which 30 µl 5-bromo-4-chloro-3-indolyl phosphate 4-toluidine salt (Roth, 50 µg/ml
10 in dimethylformamide) and 5 µl nitro blue tetrazolium (Roth, 75 µg/ml in 70 % v/v dimethylformamide) were added, until distinct colour signals could be recognized at the positions of some of the colonies. In this way the binding activity for the protein ligand, i.e. Tlpc, of the hNGAL muteins produced
15 by these colonies was detected.

Twelve of the colonies giving rise to colour spots were cultured from the first membrane. Their plasmid DNA was isolated and the hNGAL gene cassette was subjected to
20 sequence analysis by use of the Genetic Analyzer 310 system (Applied Biosystems) according to the instructions of the manufacturer using the oligodeoxynucleotide SEQ ID NO:11 as primer. The twelve sequenced clones exhibited only eight different sequences, which were named TlpcA, TlpcB, TlpcC,
25 TlpcD, TlpcE, TlpcF, TlpcG, TlpcH. The clone TlpcA was found five times. The nucleotide sequences of the clones were translated into amino acid sequences and those amino acids deviating from hNGAL are given in Table 1. The amino acid sequence and the nucleotide sequence of the mutein TlpcA are
30 also in given as SEQ ID NO:12 and SEQ ID NO:13. The sequencing revealed amber stop codons, which were suppressed in the employed *E. coli* strains, at different positions in all of the selected variants.

Example 4: Production of the hNGAL muteins

For the preparative production of hNGAL and its muteins one selected colony as well as the hNGAL originally encoded on phNGAL7, as a control, were produced in the *E. coli* strain TG1-F⁻.

To this end, 100 ml of LB/Amp-medium were inoculated with a single colony of the TG1-F⁻ transformant carrying the respective plasmid, and incubated overnight at 30 °C, 200 rpm. 2 l of LB/Amp-medium in a 5 l-Erlenmeyer flask were then inoculated with each 40 ml of this preculture and were shaken at 22 °C, 200 rpm to an OD₅₅₀ = 0.5. Induction was performed by adding 200 µg/l anhydrotetracycline (200 µl of a 2 mg/ml stock solution in DMF) followed by shaking for 3 further hours at 22 °C, 200 rpm.

The cells from one flask were centrifuged (15 minutes, 4420 g, 4 °C) and, after decanting the supernatant, were resuspended in 20 ml of periplasmic release buffer (100 mM Tris/HCl pH 8.0, 500 mM sucrose, 1 mM EDTA) with cooling for 30 minutes on ice. Subsequently the spheroplasts were removed in two successive centrifugation steps (15 minutes, 4420 g, 4 °C and 15 minutes, 30000 g, 4 °C). The supernatant comprising the periplasmatic protein extract was dialyzed against CP-buffer (100 mM Tris/HCl pH 8.0, 150 mM NaCl, 1 mM EDTA), sterile-filtered, and served for the chromatographic purification.

The purification took place by means of the Strep-Tag® II-affinity tag (Schmidt et al., supra) which was situated between the hNGAL variant and the albumin binding domain. In the present case the streptavidin mutein "1" was employed (German Patent 196 41 876.3; Voss and Skerra, Protein Eng. 10 (1997), 975-982), which was coupled to an NHS-activated sepharose (Pharmacia) yielding 5 mg/ml immobilized streptavidin, relative to the bed volume of the matrix.

A 4 ml bed volume chromatography column filled with this material was equilibrated with 20 ml CP-buffer at 4 °C at a flow rate of 40 ml/h. Chromatography was monitored by measuring the absorption at 280 nm of the eluate in a flow-through photometer. After the application of the periplasmatic protein extract, the column was washed with CP-buffer until the base line was reached and the bound hNGAL mutein was subsequently eluted with 10 ml of a solution of 2.5 mM D-desthiobiotin (Sigma) in CP-buffer. The fractions containing the purified hNGAL mutein were checked via SDS-polyacrylamide gel electrophoresis (Fling und Gregerson, Anal. Biochem. 155 (1986), 83-88) and were pooled. The protein yields were between 30 µg and 70 µg per 1 l culture.

Table 1: Sequence characteristics of selected hNGAL muteins

	Pos.	hNGAL	TlpcA	TlpcB	TlpcC	TlpcD	TlpcE	TlpcF	TlpcG	TlpcH
20	40	Ala	Cys	Gly	Leu	Ser	Val	Gly	Arg	Ala
	42	Leu	Val	Tyr	Pro	Val	Leu	Ser	Ser	Cys
	44	Glu	Gln	Tyr	Ile	Phe	Gln*	Phe	Ile	Pro
	46	Lys	Leu	Gln*	Gln*	Gln*	Cys	Arg	Phe	Leu
	47	Asp	Leu	Arg	Ala	Ser	Trp	Phe	Gln*	Phe
25	49	Gln	Ser	Trp	Ile	Ser	Cys	Val	Val	Phe
	50	Lys	Met	Ser	Phe	Ala	Pro	Gln	Phe	Leu
	70	Leu	Leu	Leu	Glu	Gly	Asp	Ser	Pro	Gln*
	72	Arg	Met	Arg	Ala	Asn	Glu	Gln*	Ala	Arg
	73	Lys	Asp	Asp	Tyr	Lys	Lys	Gln	Asn	Pro
30	77	Asp	Arg	Pro	Val	Asn	Asn	Trp	Ile	Ser
	79	Trp	Tyr	Met	Lys	Thr	Val	Arg	Ala	Arg
	101	Pro	Gly	Leu	Tyr	Tyr	Pro	Phe	Val	Leu
	102	Gly	Ile	Ser	Leu	Trp	Val	Pro	Val	Thr
	103	Leu	Val	Leu	Tyr	Gln*	Leu	Ser	Thr	Met
35	125	Lys	Ser	Trp	Leu	Gly	Glu	Arg	Ala	Lys
	127	Ser	Met	Ala	Cys	Arg	Ala	Lys	Lys	Ser
	128	Gln	Thr	Asp	Pro	Met	Ser	Ala	Thr	Asp

130	Arg	Gln*	Gln	Gly	Glu	Gln	His	Lys	Asp
132	Tyr	Ala	Trp	Lys	Thr	Leu	Ser	Leu	Ile
55	Ile							Val°	
98	Lys							Asn°	

5

*These glutamine residues were encoded by amber stop codons.

°These amino acid substitutions arose due to random mutations.

10 Example 5: Measurement of the affinity of the hNGAL muteins for Tear Lipocalin

For the detection of binding in an ELISA (Enzyme-linked Immunosorbent Assay) the wells of a microtiter plate (Micro
 15 Test III Flexible Assay Plate; Falcon) were filled each with 100 µl of a 20 mg/ml solution HSA in PBST and were incubated for 1 h at room temperature (RT). After washing three times with PBST, 50 µl of a 1 µM solution of the purified fusion
 20 protein of the hNGAL mutein TlpcA and of hNGAL from Example 3 were filled into the wells such that and the protein was immobilized via complex formation between the abd and HSA. After one hour the solution was removed and washed three times with PBST. Then a dilution series in PBST was prepared
 25 of a conjugate of Tear lipocalin and biotin in PBST, starting from 140 µg/ml, (Example 3), followed by 1 hour incubation at RT. After washing three times with PBST, avidin-alkaline phosphate conjugate (Sigma), diluted 1:10000 with PBST, was filled into the wells. Incubation was performed for 1 hour at RT and followed by washing two times with PBST and two times
 30 with PBS. Detection of the Tear lipocalin bound to the immobilized hNGAL muteins was thus accomplished via hydrolysis of p-nitrophenyl phosphate, catalyzed by the alkaline phosphatase. For this purpose, 100 µl of a solution of 0.5 mg/ml p-nitrophenyl phosphate (Amresco) in AP-buffer
 35 (100 mM NaCl, 5 mM MgCl₂, 100 mM Tris/HCl pH 8.8) were filled into the wells and the product formation was monitored by

measuring the absorption at 405 nm in a SpectraMax 250 photometer (Molecular Devices).

Claims

1. Method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat α_2 -microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target, comprising the steps of:

(a) subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in a plurality of muteins of the protein; and

(b) enriching resulting muteins having binding affinity for a given target from the plurality of muteins by selection and/or isolating said mutein.

2. Method according to claim 1, wherein the protein is subjected to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 40 to 50, 70 to 79, 101 to 103, and 125 to 132 of hNGAL.

3. Method according to claim 1 or 2, wherein the protein is subjected to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 40, 42, 44, 46, 47, 49, 50, 70, 72, 73, 77, 79, 101, 102, 103, 125, 127, 128, 130, and 132 of hNGAL.

4. Method according to any of claims 1 to 3, wherein a nucleic acid coding for the plurality of muteins of the protein, which nucleic acid results from mutagenesis, is operably fused at the 3' end with a gene coding for the coat protein pIII of a filamentous bacteriophage of the M13-family or for a fragment of this coat protein, in order to select at least one mutein for the binding of the given target.

5. Mutein of human neutrophil gelatinase-associated lipocalin (hNGAL), rat α_2 -microglobulin-related protein (A2m) or mouse 24p3/uterocalin (24p3) having detectable binding affinity to a given target, obtainable by the method of any of claims 1 to 4.

6. Mutein of hNGAL according to claim 5, wherein Cys87 is substituted and/or wherein the mutein carries one or more of the amino acid substitution Glu28 \rightarrow His, Thr145 \rightarrow Ala compared to hNGAL.

7. Mutein of hNGAL according to claim 5 having the amino acid sequence of SEQ ID NO.12.

8. Mutein according to any of claims 5 to 7, which is conjugated to a label selected from the group consisting of an organic molecule, an enzyme label, radioactive label, fluorescent label, chromogenic label, luminescent label, a haptene, digoxigenin, biotin, metal complexes, metals, and colloidal gold.

9. Fusion protein comprising a mutein of hNGAL, A2m or 24p3 according to any of claims 5 to 8, wherein an enzyme, a protein or a protein domain, a peptide, a signal sequence and/or an affinity tag is operably fused to the amino terminus or the carboxy terminus of the mutein.

10. Nucleic acid molecule comprising a sequence encoding a mutein of hNGAL, A2m or 24p3 or a fusion protein thereof according to any of claims 5 to 9.

11. Pharmaceutical composition comprising a mutein of hNGAL, A2m or 24p3 or a fusion protein thereof according to any of claims 5 to 9 and a pharmaceutically acceptable carrier.

12. Method for producing a mutein of hNGAL, A2m or 24p3 or a fusion protein thereof according to any of claims 5 to 9, wherein the mutein or the fusion protein is produced starting from the nucleic acid encoding the mutein by means of genetic engineering methods in a bacterial or eukaryotic host organism and is isolated from this host organism or its culture.

13. Use of a mutein of hNGAL, A2m or 24p3 or a fusion protein thereof according to any of claims 5 to 9 for the detection of a given target, comprising the steps of contacting the mutein with a sample suspected of containing the given target under suitable conditions, thereby allowing formation of a complex between the mutein and the given target, and determining the complexed mutein by a suitable signal.

14. Use of claim 13, wherein the given target is a protein or protein domain, a peptide, a nucleic acid molecule, an organic molecule or a metal complex and the detection is carried out for validation of the protein as pharmacological drug target.

Figure 1




Figure 2



1. PCR2. PCR

Figure 3




Figure 4





Figure 5



Sequence listing

<110> Pieris Proteolab AG

<120> Muteins of human neutrophil gelatinase-associated lipocalin and related proteins

<160> 12

<210> 1

<211> 71

<212> DNA

<213> artificial sequence

<220>

<223> Primer

<400> 1

GGTAGGTCTC GCAGGGAATN NKATTNNKAG ANNKGACNNK NNKCCGNNKN 50
NKATGTATGC CACCATCTAT G 71

<210> 2

<211> 77

<212> DNA

<213> artificial sequence

<220>

<223> Primer

<400> 2

GGCTGGGAAC CTGGAACAAA AGTCCTGATM NNGTAMNNAC ACTTCTTMNN 50
MNNAAMNNG ACGGAGGTGA CATTGTA 77

<210> 3

<211> 79

<212> DNA

<213> artificial sequence

<220>

<223> Primer

<400> 3

TGTTCCAGGT TCCCAGCCAG GCGAGTTCAC GCTGGGCAAC ATTAAGAGTT 50
ACNNKNNKNN KACGAGTTAC CTCGTCCGA 79

<210> 4

<211> 77

<212> DNA

<213> artificial sequence

<220>

<223> Primer

<400> 4

CCTTG GTTCT CCCGTAGATG GTAATCTTGA AMNNCTCMNN GTTMNNMNNA 50
ACMNNCTTAA AGAACACCAT AGCATGC 77

<210> 5
<211> 54
<212> DNA
<213> artificial sequence

<220>
<223> Primer

<400> 5

CTTCCAGGAC AACCAATTCC ATGGGAAGTG GTATGTGGTA GGTCTCGCAG 50
GGAA 54

<210> 6
<211> 39
<212> DNA
<213> artificial sequence

<220>
<223> Primer

<400> 6

CCTTTAGTTC CGAAGCCAGC TCCTTGGTTC TCCCGTAGA 39

<210> 7
<211> 1231
<212> DNA
<213> fragment of the plasmid pHNGAL5

<220>
<221> sig_peptide
<222> (22)...(84)

<220>
<221> mat_peptide
<222> (85)...(1221)
<223> fusion protein of modified hNGAL, Strep-Tag II and fragment of phage coat protein pIII

<220>
<221> CDS
<222> (85)...(618)
<223> mature hNGAL

<220>
<221> CDS
<222> (619)...(648)
<223> Strep-Tag II affinity tag

<220>
<221> CDS
<222> (649)...(651)
<223> amber stop codon

<220>

<221> CDS
 <222> (652)...(1221)
 <223> amino acids 217-406 of coat protein pIII

<400> 7

```

TCTAGATAACG AGGGCAAAA A  ATG AAA AAG ACA GCT ATC GCG ATT      45
                        Met Lys Lys Thr Ala Ile Ala Ile
                        -21 -20                               -15
GCA GTG GCA CTG GCT GGT TTC GCT ACC GTA GCG CAG GCC CAG GAC    90
Ala Val Ala Leu Ala Gly Phe Ala Thr Val Ala Gln Ala Gln Asp
                        -10                               -5           -1   1

TCC ACC TCA GAC CTG ATC CCA GCC CCA CCT CTG AGC AAG GTC CCT    135
Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val Pro
                        5                               10           15

CTG CAG CAG AAC TTC CAG GAC AAC CAA TTC CAT GGG AAG TGG TAT    180
Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys Trp Tyr
                        20                               25           30

CTG GTA GGT CTC GCA GGG AAT GCA ATT CTC AGA GAA GAC AAA GAC    225
Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp
                        35                               40           45

CCG CAA AAG ATG TAT GCC ACC ATC TAT GAG CTG AAA GAA GAC AAG    270
Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys
                        50                               55           60

AGC TAC AAT GTC ACC TCC GTC CTG TTT AGG AAA AAG AAG TGT GAC    315
Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp
                        65                               70           75

TAC TGG ATC AGG ACT TTT GTT CCA GGT TGC CAG CCC GGC GAG TTC    360
Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe
                        80                               85           90

ACG CTG GGC AAC ATT AAG AGT TAC CCT GGA TTA ACG AGT TAC CTC    405
Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu
                        95                               100          105

GTC CGA GTG GTG AGC ACC AAC TAC AAC CAG CAT GCT ATG GTG TTC    450
Val Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe
                        110                              115          120

TTT AAG AAA GTT TCT CAA AAC AGG GAG TAC TTC AAG ATT ACC ATC    495
Phe Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Ile
                        125                              130          135

TAC GGG AGA ACC AAG GAG CTG GCT TCG GAA CTA AAG GAG AAC TTC    540
Tyr Gly Arg Thr Lys Glu Leu Ala Ser Glu Leu Lys Glu Asn Phe
                        140                              145          150

ATC CGC TTC TCT AAA TCT CTG GGC CTC CCT GAA AAC CAC ATC GTC    585
Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val
                        155                              160          165

TTC CCT GTC CCA ATC GAC CAG TGT ATC GAC GGC AGC GCT TGG TCC    630
Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly Ser Ala Trp Ser
                        170                              175          180

```

CAC CCG CAG TTC GAA AAA TAG GCT GGC GGC GGC TCT GGT GGT GGT	675
His Pro Gln Phe Glu Lys Gln Ala Gly Gly Gly Ser Gly Gly Gly	
185 190 195	
TCT GGC GGC GGC TCT GAG GGT GGT GGC TCT GAG GGT GGC GGT TCT	720
Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser	
200 205 210	
GAG GGT GGC GGC TCT GAG GGA GGC GGT TCC GGT GGT GGC TCT GGT	765
Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly	
215 220 225	
TCC GGT GAT TTT GAT TAT GAA AAG ATG GCA AAC GCT AAT AAG GGG	810
Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly	
230 235 240	
GCT ATG ACC GAA AAT GCC GAT GAA AAC GCG CTA CAG TCT GAC GCT	855
Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala	
245 250 255	
AAA GGC AAA CTT GAT TCT GTC GCT ACT GAT TAC GGT GCT GCT ATC	900
Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile	
260 265 270	
GAT GGT TTC ATT GGT GAC GTT TCC GGC CTT GCT AAT GGT AAT GGT	945
Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly	
275 280 285	
GCT ACT GGT GAT TTT GCT GGC TCT AAT TCC CAA ATG GCT CAA GTC	990
Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val	
290 295 300	
GGT GAC GGT GAT AAT TCA CCT TTA ATG AAT AAT TTC CGT CAA TAT	1035
Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr	
305 310 315	
TTA CCT TCC CTC CCT CAA TCG GTT GAA TGT CGC CCT TTT GTC TTT	1080
Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe	
320 325 330	
GGC GCT GGT AAA CCA TAT GAA TTT TCT ATT GAT TGT GAC AAA ATA	1125
Gly Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile	
335 340 345	
AAC TTA TTC CGT GGT GTC TTT GCG TTT CTT TTA TAT GTT GCC ACC	1170
Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr	
350 355 360	
TTT ATG TAT GTA TTT TCT ACG TTT GCT AAC ATA CTG CGT AAT AAG	1215
Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys	
365 370 375	
GAG TCT TAATAAGCTT	1231
Glu Ser	
377	

<210> 8

<211> 1231

<212> DNA

<213> fragment of the plasmid phNGAL3

<220>
 <221> sig_peptide
 <222> (22)...(84)

<220>
 <221> mat_peptide
 <222> (85)...(1221)
 <223> fusion protein of hNGAL, Strep-Tag II and fragment of phage coat protein pIII

<220>
 <221> CDS
 <222> (85)...(618)
 <223> mature hNGAL

<220>
 <221> CDS
 <222> (619)...(648)
 <223> Strep-Tag II affinity tag

<220>
 <221> CDS
 <222> (649)...(651)
 <223> amber stop codon

<220>
 <221> CDS
 <222> (652)...(1221)
 <223> amino acids 217-406 of coat protein pIII

<400> 8

TCTAGATAACG AGGGCAAAA A	ATG AAA AAG ACA GCT ATC GCG ATT	45
	Met Lys Lys Thr Ala Ile Ala Ile	
	-21 -20 -15	
GCA GTG GCA CTG GCT GGT TTC GCT ACC GTA GCG CAG GCC CAG GAC	90	
Ala Val Ala Leu Ala Gly Phe Ala Thr Val Ala Gln Ala Gln Asp		
-10 -5 -1 1		
TCC ACC TCA GAC CTG ATC CCA GCC CCA CCT CTG AGC AAG GTC CCT	135	
Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val Pro		
5 10 15		
CTG CAG CAG AAC TTC CAG GAC AAC CAA TTC CAG GGG AAG TGG TAT	180	
Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr		
20 25 30		
CTG GTA GGT CTC GCA GGG AAT GCA ATT CTC AGA GAA GAC AAA GAC	225	
Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp		
35 40 45		
CCG CAA AAG ATG TAT GCC ACC ATC TAT GAG CTG AAA GAA GAC AAG	270	
Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys		
50 55 60		
AGC TAC AAT GTC ACC TCC GTC CTG TTT AGG AAA AAG AAG TGT GAC	315	
Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp		

65	70	75	
TAC TGG ATC AGG ACT TTT GTT CCA GGT TGC CAG CCC GGC GAG TTC	360		
Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe			
80 85 90			
ACG CTG GGC AAC ATT AAG AGT TAC CCT GGA TTA ACG AGT TAC CTC	405		
Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu			
95 100 105			
GTC CGA GTG GTG AGC ACC AAC TAC AAC CAG CAT GCT ATG GTG TTC	450		
Val Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe			
110 115 120			
TTT AAG AAA GTT TCT CAA AAC AGG GAG TAC TTC AAG ATT ACC ATC	495		
Phe Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Ile			
125 130 135			
TAC GGG AGA ACC AAG GAG CTG CCT TCG GAA CTA AAG GAG AAC TTC	540		
Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe			
140 145 150			
ATC CGC TTC TCC AAA TCT CTG GGC CTC CCT GAA AAC CAC ATC GTC	585		
Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val			
155 160 165			
TTC CCT GTC CCA ATC GAC CAG TGT ATC GAC GGC AGC GCT TGG TCC	630		
Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly Ser Ala Trp Ser			
170 175 180			
CAC CCG CAG TTC GAA AAA TAG GCT GGC GGC GGC TCT GGT GGT GGT	675		
His Pro Gln Phe Glu Lys Gln Ala Gly Gly Gly Ser Gly Gly Gly			
185 190 195			
TCT GGC GGC GGC TCT GAG GGT GGT GGC TCT GAG GGT GGC GGT TCT	720		
Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser			
200 205 210			
GAG GGT GGC GGC TCT GAG GGA GGC GGT TCC GGT GGT GGC TCT GGT	765		
Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly			
215 220 225			
TCC GGT GAT TTT GAT TAT GAA AAG ATG GCA AAC GCT AAT AAG GGG	810		
Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly			
230 235 240			
GCT ATG ACC GAA AAT GCC GAT GAA AAC GCG CTA CAG TCT GAC GCT	855		
Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala			
245 250 255			
AAA GGC AAA CTT GAT TCT GTC GCT ACT GAT TAC GGT GCT GCT ATC	900		
Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile			
260 265 270			
GAT GGT TTC ATT GGT GAC GTT TCC GGC CTT GCT AAT GGT AAT GGT	945		
Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly			
275 280 285			
GCT ACT GGT GAT TTT GCT GGC TCT AAT TCC CAA ATG GCT CAA GTC	990		
Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val			
290 295 300			
GGT GAC GGT GAT AAT TCA CCT TTA ATG AAT AAT TTC CGT CAA TAT	1035		

Gly Asp	Gly Asp	Asn Ser	Pro Leu	Met Asn	Asn Phe	Arg Gln	Tyr	
305			310			315		
TTA CCT	TCC CTC	CCT CAA	TCG GTT	GAA TGT	CGC CCT	TTT GTC	TTT	1080
Leu Pro	Ser Leu	Pro Gln	Ser Val	Glu Cys	Arg Pro	Phe Val	Phe	
320			325			330		
GGC GCT	GGT AAA	CCA TAT	GAA TTT	TCT ATT	GAT TGT	GAC AAA	ATA	1125
Gly Ala	Gly Lys	Pro Tyr	Glu Phe	Ser Ile	Asp Cys	Asp Lys	Ile	
335			340			345		
AAC TTA	TTC CGT	GGT GTC	TTT GCG	TTT CTT	TTA TAT	GTT GCC	ACC	1170
Asn Leu	Phe Arg	Gly Val	Phe Ala	Phe Leu	Leu Tyr	Val Ala	Thr	
350			355			360		
TTT ATG	TAT GTA	TTT TCT	ACG TTT	GCT AAC	ATA CTG	CGT AAT	AAG	1215
Phe Met	Tyr Val	Phe Ser	Thr Phe	Ala Asn	Ile Leu	Arg Asn	Lys	
365			370			375		
GAG TCT	TAATAAGCTT							1231
Glu Ser								
377								

<210> 9

<211> 805

<212> DNA

<213> fragment of the plasmid pHNGAL7

<220>

<221> sig_peptide

<222> (22)...(84)

<220>

<221> mat_peptide

<222> (85)...(795)

<223> fusion protein of modified hNGAL, Strep-Tag II and albumin binding domain

<220>

<221> CDS

<222> (85)...(618)

<223> mature hNGAL

<220>

<221> CDS

<222> (619)...(648)

<223> Strep-Tag II affinity tag

<220>

<221> CDS

<222> (649)...(795)

<223> albumin binding domain of Protein G

<400> 9

TCTAGATAAC	GAGGGCAAAA	A	ATG AAA	AAG ACA	GCT ATC	GCG ATT	45
			Met Lys	Lys Thr	Ala Ile	Ala Ile	
			-21	-20		-15	

GCA GTG	GCA CTG	GCT GGT	TTC GCT	ACC GTA	GCG CAG	GCC CAG	GAC	90
---------	---------	---------	---------	---------	---------	---------	-----	----

Ala	Val	Ala	Leu	Ala	Gly	Phe	Ala	Thr	Val	Ala	Gln	Ala	Gln	Asp	
			-10					-5				-1	1		
TCC	ACC	TCA	GAC	CTG	ATC	CCA	GCC	CCA	CCT	CTG	AGC	AAG	GTC	CCT	135
Ser	Thr	Ser	Asp	Leu	Ile	Pro	Ala	Pro	Pro	Leu	Ser	Lys	Val	Pro	
		5					10					15			
CTG	CAG	CAG	AAC	TTC	CAG	GAC	AAC	CAA	TTC	CAG	GGG	AAG	TGG	TAT	180
Leu	Gln	Gln	Asn	Phe	Gln	Asp	Asn	Gln	Phe	Gln	Gly	Lys	Trp	Tyr	
		20					25					30			
CTG	GTA	GGT	CTC	GCA	GGG	AAT	GCA	ATT	CTC	AGA	GAA	GAC	AAA	GAC	225
Val	Val	Gly	Leu	Ala	Gly	Asn	Ala	Ile	Leu	Arg	Glu	Asp	Lys	Asp	
		35					40					45			
CCG	CAA	AAG	ATG	TAT	GCC	ACC	ATC	TAT	GAG	CTG	AAA	GAA	GAC	AAG	270
Pro	Gln	Lys	Met	Tyr	Ala	Thr	Ile	Tyr	Glu	Leu	Lys	Glu	Asp	Lys	
		50					55					60			
AGC	TAC	AAT	GTC	ACC	TCC	GTC	CTG	TTT	AGG	AAA	AAG	AAG	TGT	GAC	315
Ser	Tyr	Asn	Val	Thr	Ser	Val	Leu	Phe	Arg	Lys	Lys	Lys	Cys	Asp	
		65					70					75			
TAC	TGG	ATC	AGG	ACT	TTT	GTT	CCA	GGT	TGC	CAG	CCC	GGC	GAG	TTC	360
Tyr	Trp	Ile	Arg	Thr	Phe	Val	Pro	Gly	Cys	Gln	Pro	Gly	Glu	Phe	
		80					85					90			
ACG	CTG	GGC	AAC	ATT	AAG	AGT	TAC	CCT	GGA	TTA	ACG	AGT	TAC	CTC	405
Thr	Leu	Gly	Asn	Ile	Lys	Ser	Tyr	Pro	Gly	Leu	Thr	Ser	Tyr	Leu	
		95					100					105			
GTC	CGA	GTG	GTG	AGC	ACC	AAC	TAC	AAC	CAG	CAT	GCT	ATG	GTG	TTC	450
Val	Arg	Val	Val	Ser	Thr	Asn	Tyr	Asn	Gln	His	Ala	Met	Val	Phe	
		110					115					120			
TTT	AAG	AAA	GTT	TCT	CAA	AAC	AGG	GAG	TAC	TTC	AAG	ATT	ACC	ATC	495
Phe	Lys	Lys	Val	Ser	Gln	Asn	Arg	Glu	Tyr	Phe	Lys	Ile	Thr	Ile	
		125					130					135			
TAC	GGG	AGA	ACC	AAG	GAG	CTG	CCT	TCG	GAA	CTA	AAG	GAG	AAC	TTC	540
Tyr	Gly	Arg	Thr	Lys	Glu	Leu	Thr	Ser	Glu	Leu	Lys	Glu	Asn	Phe	
		140					145					150			
ATC	CGC	TTC	TCC	AAA	TCT	CTG	GGC	CTC	CCT	GAA	AAC	CAC	ATC	GTC	585
Ile	Arg	Phe	Ser	Lys	Ser	Leu	Gly	Leu	Pro	Glu	Asn	His	Ile	Val	
		155					160					165			
TTC	CCT	GTC	CCA	ATC	GAC	CAG	TGT	ATC	GAC	GGC	AGC	GCT	TGG	TCC	630
Phe	Pro	Val	Pro	Ile	Asp	Gln	Cys	Ile	Asp	Gly	Ser	Ala	Trp	Ser	
		170					175					180			
CAC	CCG	CAG	TTC	GAA	AAA	CCA	GCT	AGC	CTG	GCT	GAA	GCT	AAA	GTT	675
His	Pro	Gln	Phe	Glu	Lys	Pro	Ala	Ser	Leu	Ala	Glu	Ala	Lys	Val	
		185					190					195			
CTG	GCT	AAC	CGT	GAA	CTG	GAC	AAA	TAC	GGT	GTT	TCC	GAC	TAC	TAC	720
Leu	Ala	Asn	Arg	Glu	Leu	Asp	Lys	Tyr	Gly	Val	Ser	Asp	Tyr	Tyr	
		200					205					210			
AAA	AAC	CTC	ATC	AAC	AAC	GCT	AAA	ACC	GTT	GAA	GGT	GTT	AAA	GCT	765
Lys	Asn	Leu	Ile	Asn	Asn	Ala	Lys	Thr	Val	Glu	Gly	Val	Lys	Ala	
		215					220					225			

CTG ATC GAC GAA ATT CTC GCA GCA CTG CCG TAATAAGCTT 805
 Leu Ile Asp Glu Ile Leu Ala Ala Leu Pro
 230 235

<210> 10
 <211> 580
 <212> DNA
 <213> fragment of the plasmid pTLpc3

<220>
 <221> sig_peptide
 <222> (22)...(84)

<220>
 <221> mat_peptide
 <222> (85)...(570)
 <223> fusion protein of modified human Tear Lipocalin and Strep-Tag II

<220>
 <221> CDS
 <222> (85)...(543)
 <223> mature human Tear Lipocalin

<220>
 <221> CDS
 <222> (544)...(570)
 <223> Strep-Tag II affinity tag

<400> 10

TCTAGATAACG AGGGCAAAA A ATG AAA AAG ACA GCT ATC GCG ATT 45
 Met Lys Lys Thr Ala Ile Ala Ile
 -21 -20 -15
 GCA GTG GCA CTG GCT GGT TTC GCT ACC GTA GCG CAG GCC GCC TCA 90
 Ala Val Ala Leu Ala Gly Phe Ala Thr Val Ala Gln Ala Ala Ser
 -10 -5 -1 1

 GAC GAG GAG ATT CAG GAT GTG TCA GGG ACG TGG TAT CTG AAG GCC 135
 Asp Glu Glu Ile Gln Asp Val Ser Gly Thr Trp Tyr Leu Lys Ala
 5 10 15

 ATG ACG GTG GAC AGG GAG TTC CCT GAG ATG AAT CTG GAA TCG GTG 180
 Met Thr Val Asp Arg Glu Phe Pro Glu Met Asn Leu Glu Ser Val
 20 25 30

 ACA CCC ATG ACC CTC ACG ACC CTG GAA GGG GGC AAC CTG GAA GCC 225
 Thr Pro Met Thr Leu Thr Thr Leu Glu Gly Gly Asn Leu Glu Ala
 35 40 45

 AAG GTC ACC ATG CTG ATA AGT GGC CGG TGC CAG GAG GTG AAG GCC 270
 Lys Val Thr Met Leu Ile Ser Gly Arg Cys Gln Glu Val Lys Ala
 50 55 60

 GTC CTG GAG AAA ACT GAC GAG CCG GGA AAA TAC ACG GCC GAC GGG 315
 Val Leu Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr Ala Asp Gly
 65 70 75

GGC AAG CAC GTG GCA TAC ATC ATC AGG TCG CAC GTG AAG GAC CAC 360
 Gly Lys His Val Ala Tyr Ile Ile Arg Ser His Val Lys Asp His
 80 85 90

TAC ATC TTT TAC TCT GAG GGC GAG CTC CAC GGG AAG CCG GTC CGA 405
 Tyr Ile Phe Tyr Ser Glu Gly Glu Leu His Gly Lys Pro Val Arg
 95 100 105

CGG GTG AAG CTC GTG GGC AGA GAC CCC AAG AAC AAC CTG GAA GCC 450
 Gly Val Lys Leu Val Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala
 110 115 120

TTG GAG GAC TTT GAG AAA GCC GCA GGA GCC CGC GGA CTC AGC ACG 495
 Leu Glu Asp Phe Glu Lys Ala Ala Gly Ala Arg Gly Leu Ser Thr
 125 130 135

GAG AGC ATC CTC ATC CCC AGG CAG AGC GAA ACC TGC TCT CCA GGG 540
 Glu Ser Ile Leu Ile Pro Arg Gln Ser Glu Thr Cys Ser Pro Gly
 140 145 150

AGC GCT TGG TCT CAC CCG CAG TTC GAA AAA TAATAAGCTT 580
 Ser Ala Trp Ser His Pro Gln Phe Glu Lys
 155 160

<210> 11
 <211> 18
 <212> DNA
 <213> artificial sequence

<220>
 <223> Primer

<400> 11

CCACTCCCTA TCAGTGAT 18

<210> 12
 <211> 537
 <212> DNA
 <213> coding sequence of the mutein TlpcA

<220>
 <221> CDS
 <222> (1)...(537)
 <223> mutein TlpcA
 <400> 12

CAG GAC TCC ACC TCA GAC CTG ATC CCA GCC CCA CCT CTG AGC AAG 45
 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys
 1 5 10 15

GTC CCT CTG CAG CAG AAC TTC CAG GAC AAC CAA TTC CAT GGG AAG 90
 Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe His Gly Lys
 20 25 30

TGG TAT GTG GTA GGT CTC GCA GGG AAT TGT ATT GTG AGA CAG GAC 135
 Trp Tyr Val Val Gly Leu Ala Gly Asn Cys Ile Val Arg Gln Asp
 35 40 45

CTT CTG CCG TCT ATG ATG TAT GCC ACC ATC TAT GAG CTG AAA GAA 180
 Leu Leu Pro Ser Met Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu

50															55					60				
GAC	AAG	AGC	TAC	AAT	GTC	ACC	TCC	GTC	TTA	TTT	ATG	GAT	AAG	AAG	225									
Asp	Lys	Ser	Tyr	Asn	Val	Thr	Ser	Val	Leu	Phe	Met	Asp	Lys	Lys										
															65	70	75							
TGT	CGG	TAC	TAT	ATC	AGG	ACT	TTT	GTT	CCA	GGT	TCC	CAG	CCG	GGC	270									
Cys	Arg	Tyr	Tyr	Ile	Arg	Thr	Phe	Val	Pro	Gly	Ser	Gln	Pro	Gly										
															80	85	90							
GAG	TTC	ACG	CTG	GGC	AAC	ATT	AAG	AGT	TAC	GGT	ATT	GTT	ACG	AGT	315									
Glu	Phe	Thr	Leu	Gly	Asn	Ile	Lys	Ser	Tyr	Gly	Ile	Val	Thr	Ser										
															95	100	105							
TAC	CTC	GTC	CGA	GTG	GTG	AGC	ACC	AAC	TAC	AAC	CAG	CAT	GCT	ATG	360									
Tyr	Leu	Val	Arg	Val	Val	Ser	Thr	Asn	Tyr	Asn	Gln	His	Ala	Met										
															110	115	120							
GTG	TTC	TTT	AAG	TCG	GTT	ATG	ACG	AAC	TAG	GAG	GCG	TTC	AAG	ATT	405									
Val	Phe	Phe	Lys	Ser	Val	Met	Thr	Asn	Gln	Glu	Ala	Phe	Lys	Ile										
															125	130	135							
ACC	ATC	TAC	GGG	AGA	ACC	AAG	GAG	CTG	GCT	TCG	GAA	CTA	AAG	GAG	450									
Thr	Ile	Tyr	Gly	Arg	Thr	Lys	Glu	Leu	Ala	Ser	Glu	Leu	Lys	Glu										
															140	145	150							
AAC	TTC	ATC	CGC	TTC	TCT	AAA	TCT	CTG	GGC	CTC	CCT	GAA	AAC	CAC	495									
Asn	Phe	Ile	Arg	Phe	Ser	Lys	Ser	Leu	Gly	Leu	Pro	Glu	Asn	His										
															155	160	165							
ATC	GTC	TTC	CCT	GTC	CCA	ATC	GAC	CAG	TGT	ATC	GAC	GGC	AGC		537									
Ile	Val	Phe	Pro	Val	Pro	Ile	Asp	Gln	Cys	Ile	Asp	Gly	Ser											
															170	175								

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 01/11213	
A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/12 C07K14/47 C12N15/62 G01N33/50 A61K38/17	
According to International Patent Classification (IPC) or to both national classification and IPC	
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K G01N A61K	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched	
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, SEQUENCE SEARCH	
C. DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages
X	WO 99 16873 A (SKERRA ARNE; BESTE GERALD; SCHMIDT FRANK; STIBORA THOMAS (DE)) 8 April 1999 (1999-04-08) cited in the application the whole document
A	BESTE G. ET AL.: "Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 96, no. 5, 2 March 1999 (1999-03-02), pages 1898-1903, XP002150337 ISSN: 0027-8424 cited in the application the whole document
	Relevant to claim No. 1,2,4,5, 8-14
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>	
* Special categories of cited documents :	
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search 19 September 2002	Date of mailing of the international search report 30/09/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/11213

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BUNDGAARD J.R. ET AL.: "Molecular cloning and expression of a cDNA encoding NGAL: a Lipocalin expressed in human neutrophils" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 202, no. 3, 15 August 1994 (1994-08-15), pages 1468-1475, XP002036694 ISSN: 0006-291X page 1472; figure 2</p>	
A	<p>PAINE K. AND FLOWER D.R.: "The lipocalin website" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1482, no. 1-2, 18 October 2000 (2000-10-18), pages 351-352, XP004279087 ISSN: 0167-4838 the whole document</p>	
A	<p>SKERRA A.: "Lipocalins as a scaffold" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1482, no. 1-2, 18 October 2000 (2000-10-18), pages 337-350, XP004279086 ISSN: 0167-4838 the whole document</p>	
A	<p>WO 00 75308 A (SKERRA ARNE (DE); SCHLEHUBER STEFFEN (DE)) 14 December 2000 (2000-12-14) cited in the application the whole document</p>	
A	<p>SCHLEHUBER S. ET AL.: "A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin" JOURNAL OF MOLECULAR BIOLOGY, vol. 297, no. 5, 14 April 2000 (2000-04-14), pages 1105-1120, XP002150338 ISSN: 0022-2836 cited in the application the whole document</p>	
A	<p>WO 96 23879 A (TERRAPIN TECHNOLOGIES, INC. (US); KAUVAR; TRAINER; VILLAR; NAPOLITANO) 8 August 1996 (1996-08-08) page 34 -page 35; example 9C</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11213

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9916873	A	08-04-1999	DE	19742706 A1	15-04-1999
			AU	1143799 A	23-04-1999
			WO	9916873 A1	08-04-1999
			EP	1017814 A1	12-07-2000
WO 0075308	A	14-12-2000	DE	19926068 C1	11-01-2001
			AU	5963900 A	28-12-2000
			WO	0075308 A1	14-12-2000
			EP	1181368 A1	27-02-2002
WO 9623879	A	08-08-1996	AU	5132096 A	21-08-1996
			WO	9623879 A1	08-08-1996